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1. The engine of life; some facts 
 The heart has intrigued people for many centuries varying from romantic poetry to 
(modern) science.  The ancient Greek thought the heart to be the seat of the soul and named 
the organ kardia, many years later the Romans changed this to cor. During the medieval 
period the organ was designated heorte, which is the basis of the word heart. Servetus 
(1511-1553) identified a small circulatory circuit (pulmonary circulation) and a large 
circulatory circuit (systemic circulation). In addition, in detailed anatomical drawings 
Leonardo da Vinci projected how the body might work (Figure 1). Several years later, Harvey 
(1578-1657) was the first to describe that circulation of blood is due to pumping of the heart 
and this concept was fundamental for modern cardiovascular research. 
 
 Figure 1. One of the first hand drawings of the human heart by Leonardo Da Vinci. Da Vinci was a self-educator 
in human anatomy. He performed autopsies on the bodies of criminals.   
 
The heart can be divided into the left and right atrium (LA and RA) and left and right ventricle 
(LV and RV). The RA collects oxygen-deprived blood from the venous system and transports 
it to the RV, which pumps it into the pulmonary circulation. Here carbon dioxide is exchanged 
for oxygen and oxygen-rich blood is transported to the LA and subsequently the LV. 
Following contraction of the LV, blood flows through the body, providing organs and tissues 
with the required nutrients and oxygen. 
The heart is, unlike skeletal muscle, an involuntary muscle that is controlled by sympathetic 
and parasympathetic stimuli. Even without these stimuli the heart is able to maintain a 
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beating frequency due to unique electrophysiological characteristics of membranes. A 
heartbeat originates in the pacemaker cells of the sinoatrial node (SA-node) and this 
electrical stimulus is conducted to the atrioventricular node (AV-node), followed by a rapid 
conduction to the His bundle and bundle branches, leading to the excitation-contraction 
coupling in the cardiomyocytes of the ventricles. A normal human heart at rest can pump 
approximately 70 ml blood per beat (=stroke volume; SV) with an average frequency of 70 
beats per minuteleading to a cardiac output of approximately 5 litres blood per minute. 
Endurance training results in an increased heart muscle mass that is not achieved by cell 
division, but instead results from enlargement of myocardial cells, also described as 
(physiological) cardiac hypertrophy. Unlike this physiological adaptation of the heart due to 
intermittent exercise, the heart develops pathophysiological hypertrophy when the overload 
stimulus is maintained, for example due to chronically increased blood pressure, cardiac 
valvular diseases or loss of cardiac tissue following a myocardial infarction. Initially the heart 
tends to compensate for the increase in workload by increasing wall thickness. This 
hypertrophic process includes a concomitant increase in RNA transcription, protein synthesis 
and a so-called re-introduction of fetal gene expression. However, in the long run these 
adaptations further contribute to the development of heart failure, a situation in which 
overload can no longer be compensated by the hypertrophic adaptations, leading again to an 
increase in wall stress (decompensation). Mechanisms that underlie the transition of 
compensated hypertrophy into decompensated heart failure are not well understood.  
Mediators such as an imbalance in oxygen demand of the heart and its supply, contractile 
dysfunction and altered calcium homeostasis are involved in this process. 
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1.1. Incidence of cardiovascular disease in the Netherlands 
 As evident from epidemiological studies, cardiovascular disease is the most common 
cause of death in the Netherlands in 2004.  It has been calculated that one out of three 
people in the Dutch population will die from cardiovascular disease (www.hartstichting.nl). 
Improved management of cardiac infarction, the increase in average age of the population, 
but also overweight as a result of high fat,  or “American” diet and a dramatic decrease in 
exercise further contribute to the increased incidence of different forms of cardiomyopathies.  
 
1.2. Cardiac contraction and its most important mediators 
To provide the body with the required nutrients and oxygen, the heart pumps the 
blood into the circulation. Cardiac contraction will not occur unless a few essential 
components are able to interact in the myocardial muscle cell, i.e., fuel in the form of 
adenosine triphosphate (ATP), actin and myosin filaments for the formation of cross-bridges 
and calcium. Calcium is a versatile signaling molecule (in all cell types) that is not only 
involved in muscle contraction, but also in processes such as cellular hypertrophy, apoptosis 
and transcription regulation 1. Calcium transporters situated at the sarcolemma and the 
sarcoplasmic reticulum (SR) membrane regulate the intracellular calcium concentration 
([Ca2+]i) in such a way that this concentration ranges between 0.1 µM during diastole and 10 
µM during systole, thereby establishing a calcium gradient of approximately 100-1,000-fold 
between the intracellular and the extracellular environment 2 (Figure 2). 
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Figure 2. Processes involved in the generation of a cardiac contraction. After each depolarization of the  
sarcolemma, Ca2+ enters the myocyte via the L-type Ca2+-channel [1]. A small amount of Ca2+ induces a Ca2+-
induced Ca2+ release of the SR via the ryanodin receptors [2]. A bulk of Ca2+ migrates to and binds to 
myofilaments [3,4] and contraction occurs. After contraction, calcium dissociates from the myofilaments [5] and 
Ca2+ is redistributed (in small amounts) to the mitochondria [6a], via the Na+/Ca2+-exchanger [6b], via the 
sarcolemmal Ca2+ ATPase  [6c] and in huge amouts by the sarco-plasmic reticulum Ca2+-ATPase 2a (SERCA2a) 
[6d]. These Ca2+ transporters maintain a 100-10.000-fold Ca2+ gradient across the sarcolemma during systole and 
diastole. Figure is modified form Bers et al. 2 
 
The initial trigger to generate ventricular contraction is the rapid propagation of the electric 
pulse from the SA-node to the ventricular cardiomyocytes resulting in a voltage-dependent 
change in conduction of sarcolemmal L-type calcium channels. A small amount of 
extracellular calcium ions enters the muscle cell via these calcium channels, resulting in a 
calcium-induced calcium release from the SR via SR membrane calcium channels known as 
ryanodine receptors. Released calcium migrates to the myofilaments and the availability of 
calcium and ATP near the thin (actin) and thick (myosin) filaments enables these filaments to 
form a cross-bridge, followed by a power stroke and contraction of the muscle. This is also 
referred to as “the sliding filament model”. After a contraction, calcium dissociates from the 
2 
1 
3 
4 
5 
6a 
6c 6b 
6d 
1 mM [Ca2+]o 100 nM- 
10 µM [Ca2+]i 
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filaments and is quickly removed from the cytosol resulting in a drop of the intracellular 
calcium concentration to normal (resting) values and relaxation ensues leading to diastole.  
The main part of the calcium is pumped back into the SR by the sarco-plasmic reticulum 
calcium ATPase 2a (SERCA2a). Relatively small amounts of calcium are transported out of 
the cell by the sarcolemmal sodium calcium exchanger (NCX) and the sarcolemmal calcium 
pump.  
  
1.3. Pathological cardiac hypertrophy and changes in gene expression 
The chronic increase in workload of the heart that underlies the development of 
pathological cardiac hypertrophy and heart failure results in  a change in the expression of a 
subset of genes, including an increased expression of atrial natriuretic factor (ANF), skeletal 
α-actin and β-myosin heavy chain3,4. Since these genes are also expressed during early 
cardiac development, the increased expression of these genes following pathological cardiac 
hypertrophy and failure is therefore also referred to as the re-introduction of the fetal-gene 
program. Additionally, an increase in neurohumoral signaling 5 and a decrease in SERCA2a 
activity 6, SERCA2a protein expression 7 as well as SERCA2a mRNA expression 8 have 
been observed in various animal models of pressure or volume overload and in patients with 
heart failure 9,10. Impaired calcium sequestration, following repression of SERCA2a function 
will affect contractile function and may, in addition, play a role in the onset of apoptosis, 
affect transcription regulation and further contribute to the development of pathological 
cardiac hypertrophy 11-14.  
 Reduced SERCA2a pump activity as observed during pathological cardiac 
hypertrophy may initially result from compensatory mechanisms by which the myocardial cell 
tends to prevent excessive energy loss; however, this adaptation will turn deleterious when 
maintained for too long. A mechanism that contributes to the reduced SERCA2a activity 
during pathological cardiac hypertrophy is the increased activity of the SERCA2a inhibitory 
protein phospholamban (PLB). Impaired β-adrenergic signaling, as observed during 
pathological cardiac hypertrophy, results in hypo-phosphorylation of PLB and results in an 
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enhanced interaction with SERCA2a, leading to impaired SERCA2a function and 
consequently a reduced calcium redistribution into the SR 15. However, reduction of 
SERCA2a protein expression that is observed in most animal models of heart failure as well 
as in patients is probably the main cause of the decreased SERCA2a activity 15. In addition 
to impaired SERCA2a protein function following an increased interaction with PLB, there is 
evidence that impaired SERCA2a transcription underlies the repression of SERCA2a protein 
expression, although relatively few studies have addressed this issue 16-20.  
 
1.4. Regulation of gene expression during pathological cardiac hypertrophy  
Normally, heart muscle cells are chronically subjected to mechanical load in such a 
way that a steady state phenotype in load-dependent regulatory processes is generated. 
However, perturbations of this steady state provoked by pathological conditions such as 
hypertension and overload caused by infarction, will induce changes in gene expression. A 
few load- and calcium-sensitive signal cascades as well as stress-induced pathways involved 
in pathological hypertrophy that may contribute to the (negative) regulation of SERCA2a 
transcription will be dealt with in the next sections.  
 
 
1.5. Load-induced signaling, ECM, cytoskeleton and SRF  
During each contraction, mechanical forces generate modifications of both the 
exterior and interior environment of a cardiac myocyte. Via receptors situated in the 
sarcolemma, load is converted into chemical signals that conduct these stimuli via the 
cytoskeleton or via (mechanical) stress-activated proteins to cellular regions, such as the 
nucleus 21,22. This process is also known as mechano-transduction 23-26. The extracellular 
matrix (ECM), together with the cytoskeleton maintains cellular architecture. Furthermore the 
ECM is involved in cellular coupling, thereby indirectly enabling intercellular communication 
21. ECM-receptors have been identified and classified in integrins, discoidin domain receptors 
(DDR) and cadherins. Here, the primary focus will be on integrins. Once activated by load 
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stimuli, integrin receptors will cluster and aggregate into focal adhesion complexes. Via 
proteins such as focal adhesion kinases, integrin-like kinases and the small GTPase RhoA, 
these complexes link the extracellular environment to cellular regulatory mechanisms. 
Particularly,  RhoA is involved in regulating actin dynamics 4,27,28. Increased activity of RhoA 
has been observed in human cardiomyopathy 29. Increased actin stabilization resulting from 
enhanced RhoA signaling is one of the regulatory mechanisms by which RhoA can affect 
cardiac transcription 27. RhoA either directly phosphorylates proteins involved in excitation-
contraction coupling 30,31, or alters gene transcription by modifying nuclear translocation of 
RhoA-dependent transcription factors, such as SRF 32. SRF is 67 kDa phosphoprotein that 
belongs to the MCM1, Agamous, Deficiens and SRF (MADS) family of transcription factors 
that binds to serum response elements (SRE; CC (A/T)6 GG) located in SRF-responsive 
promoters 33. Cardiac-specific overexpression of SRF in transgenic mice has been shown to 
induce cardiomyopathy with a concomitant inhibition of SERCA2a protein expression 34. 
However, the nature of the mechanism by which SRF may control SERCA2a transcription or 
expression, i.e., directly or indirectly, remains unknown.  
 
1.6. Calcium-dependent signaling 
 Calcium is a versatile ion in (muscle) physiology 14,35 and plays a prominent role in 
gene regulation as well as in excitation-contraction coupling. During pathological cardiac 
hypertrophy important mediators underlying the increase in cytoplasmic calcium are: the 
calcium-induced calcium release from the SR, the accumulation of calcium following an 
increased activation of stretch-induced calcium channels due to high LV filling pressure and 
impaired SERCA2a protein expression. This increase in cellular calcium concentration is 
sensed by calmodulin and once calmodulin is saturated with calcium, it activates 
downstream cascades such as calcineurin (CN)/nuclear factor of activated T-lymphocytes 
(NFAT) 36 and calmodulin kinase II (CaMK II)/myocyte enhancer factor 2c (MEF2c) 12,37-40. 
Although experimental evidence is scarce, differences in local accumulation of calcium is a 
proposed mechanism that may distinguish the role of calcium in excitation-contraction 
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coupling from that in transcription regulation. Docking proteins that can bind calmodulin, CN 
or CAMK-II are suggested to be situated near calcium release channels such as the 
ryanodine receptor or the inositol 1, 4, 5-triphosphate (IP3) receptor, near contractile 
filaments or near the nuclear membrane. Changes in local calcium dynamics can therefore 
easily be detected by these calcium-sensing proteins and trigger (local) downstream 
(calcium-dependent) cascades 41.  
In the literature, controversy exists about the contribution of calcium-dependent 
signaling in the development of pathological and physiological cardiac hypertrophy. Previous 
studies have demonstrated that overexpression of CN or CAMK signaling pathways 
contribute to the development of pathological cardiac hypertrophy and these pathways have 
been linked to the concomitant decrease in SERCA2a expression 42. This calcium-induced 
pathological cardiac hypertrophy could be (partly) reversed following direct repression of CN 
and CAMK signaling or via repression of downstream CN and CAMK –dependent  factors 43-
49. In contrast, other studies have documented that activation of the calcineurin cascade is 
solely an adaptive response during physiological cardiac hypertrophy 50,51.  
Recently, endogenous CN/NFAT regulating enzymes such as modulatory calcineurin 
interacting proteins (MCIP), or glycogen synthase kinase 3β (GSK3β) have been reported to 
function as feedback inhibitors of CN signalling 3. It is therefore possible that either enhanced 
CN signaling contributes to the development of hypertrophy, or CN activity increases as a 
result of impaired negative feedback mechanisms, stressing the complexity and interference 
of multiple cascades in control of gene expression during the development of cardiac 
hypertrophy.   
The relatively early activation of CN and CAMK preceding repression of SERCA2a 
expression suggests that pro-hypertrophic signaling cascades other than calcium-dependent 
ones affect SERCA2a transcription or expression. Direct control mechanisms of CN and 
CAMK-II in SERCA2a transcription regulation and in SERCA2a expression have not been 
documented yet.  
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1.7. Stress-induced signaling and GATA4.  
  Increases in in vivo cardiac hemodynamic load or in vitro stretching of cultured 
cardiac myocytes imposes an enhanced mechanical stress on cardiomyocytes. Mechanical 
stress is considered to be the trigger for the growth response of the overloaded myocardium. 
Furthermore, mechanical stress induces the release of growth-promoting factors, such as 
angiotensin II, endothelin-1, and transforming growth factor-β, which provide a second line of 
growth induction. Among the plethora of stress-activated signaling cascades that are 
activated during the development of pathological cardiac hypertrophy, the ERK1/2, p38 
MAPK, JNK and Akt pathways are most commonly described 28,52. Responses of cardiac 
promoters of genes such as the α myosin heavy chain (α-MHC), ANF, brain natriuretic 
peptide (BNP), NCX, to their downstream transcription factors, such as NFAT, SRF, NFκB, 
MEF2 and GATA4, have been analyzed in various experimental models 53-55. Of the six 
GATA isoforms identified, GATA 4-6 have been documented to be involved in the 
progression of pathological cardiac hypertrophy. Activation of GATA4 by phosphorylation 
results in nuclear translocation of this transcription factor 56. In addition to GATA4 protein 
phosphorylation, GATA4 dependent promoter activities can also be modified by the 
interaction of GATA4  
with other “pro-hypertrophic factors” among which are the transcription co-factors p300 57, 
SRF 58, NFAT 59,60 and MEF 61.  
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Figure 3 presents a schematic overview of important signaling factors that are involved in the 
development of (pathological) cardiac hypertrophy. Their role in SERCA2a transcription 
regulation investigated in this study. 
 
Figure 3. Schematic overview of signaling pathways involved in the development of pathological cardiac 
hypertrophy. Figure is adapted from Frey and Olson 2004 3. 
 
1.8. Transcription regulation; complex (of) interactions  
 Altered gene expression profiles as observed during pathological cardiac 
hypertrophy, could result from changes in transcriptional control of these particular genes. 
Alteration of transcription control is the result of many complex regulatory mechanisms, such 
as direct binding of transcription factors to promoter DNA. Formations of protein-protein 
(transcription factors) complexes can affect transcription regulation by altering the binding-
specificity of these complexes to promoter DNA. Another regulatory mechanism underlying 
transcription control is the unwinding of histones. Eukaryotic DNA is packed into chromatin 
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which limits access of transcription factors. Chromatin consists of nucleosomes and the basic 
unit of a nucleosome is a histone. Modifications of histone-tails by phosphorylation, 
methylation, ubiquitination and acetylation allow histones to (de)compact, thereby regulating 
interactions of transcription factors with (promoter) DNA. Among histone modifications, 
(de)acetylation is a well characterized transcription-regulating mechanism 62,63. Histone 
acetyltransferases (HAT) relaxes histone condensation, generating access for transcription 
factors to core DNA. Cardiogenic transcription factors such as SRF, MEF and GATA4 are 
able to associate with HATs 62. Among the different HATs that can interact with the above 
mentioned cardiogenic transcription factors, p300 and CREB binding protein (CBP) are the 
best characterized.  Moreover, enhanced HAT activity contributes to the development of 
pathological cardiac hypertrophy. Stimulatory effects of HAT are antagonized by histone 
deacetylases (HDAC), which promote chromatin condensation and repression of 
transcription. In the heart most studies have focused on class II HDAC (HDAC4, 5, 7, 9) 64. 
During pathological cardiac hypertrophy, the calcium-dependent phosphatase calcineurin 
and stress-activated kinases such as calmodulin kinase II or IV stimulate the chaperone 14-
3-3-mediated nuclear export of HDAC, resulting in chromosomal relaxation and initiation of 
pro-hypertrophic transcription 65. The transcription factors MEF2 65,66 and SRF 67 appear to 
link HAT and HDAC activity. Both histone modifiers are able to interact with these 
transcription factors (Figure 4). A critical balance between pro- and anti-hypertrophic stimuli 
will therefore couple upstream stress-induced cardiac signaling to gene regulatory programs 
for cardiac remodeling 62,64-68. 
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Figure 4. Histone modification by (de)acetylation is one of the transcription regulatory mechanisms. Stress and 
prohypertrophic stimuli will activate various kinases and phosphatases, resulting in inactivation of histone 
deacetylases (HDAC), relaxation of chromatin structure and nuclear export of HDAC that is mediated via the 14-
3-3 chaperone protein. Relief of inhibitory HDAC enables histone acetyltransferases (HAT) to associate with pro-
hypertrophic transcription factors such as SRF, MEF, NFAT, GATA4, which results in transcription initiation of 
genes involved in pathological cardiac hypertrophy (modified from McKinsey 64)  
 
1.9. SERCA2a promoter sequence and homology  
 Information about the chromosomal localization, length and putative functions of 
genes is relatively easy to obtain now that more genomes have been sequenced completely. 
Nevertheless, information about the physiologically relevant length of the promoter regions of 
genes is scarce and difficult to acquire. Identification of conserved regions within the known 
human, rabbit, mouse and rat sequences is an often used strategy to investigate relevant 
regulatory promoter regions (Figure 5). Comparison of mouse and rat SERCA2a promoters 
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SERCA2a promoter SERCA2a gene
6.6 4.1 3.1 
Rat 12q16
Mouse 5F
Rabbit
Human chr
12q23-24.1
3.6 2.5 1.5 
sequences revealed high homology upto -4100 bp (Figure 5), suggesting that this part of the 
SERCA2a promoter is conserved. However, only the first -600 bp of these murine promoters 
were highly identical to the human SERCA2a promoter. Putative transcription factor binding 
sites in this promoter region were identified such as NFκB responsive elements (-119 bp; -
259 bp), and NFAT (-174 bp) responsive element. Binding sites in the conserved murine 
SERCA2a promoters contain cis-acting domains for factors such as thyroid hormone, SRF, 
transcription enhancer factor 1 (TEF-1), MEF, GATA4, NFAT, Sp-1, Erg (see Table for 
references). Studies that have characterized and identified stress or hypertrophy-responsive 
elements on the human, rat and rabbit SERCA2a promoters and their deletion variants are 
summarized in Table 1.  
 
Figure 5.  Schematic representation of the homologies of SERCA2a promoter sequences among four different 
species (rat, mouse, rabbit and human). The numbers above the rat SERCA2a promoter represent the rough 
length of the SERCA2a promoter. Dark colored boxes represent highly homologous promoter regions compared 
to the rat SERCA2a promoter sequence. 
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Stimulus Model promoter length (bp) species up- or downregulation reference 
ET-1 NVCM 1943 rat down 77 
AC Rat endogenous rat down 20 
LIF; IL-6 NVCM 3200 rat down 74 
T3; MEF2a H9C2  3200 rat up 81 
ATF6 NVCM 3258 rat up 82 
T3; LIF; IL-6 NVCM 3200 rat down 75 
PO DOCA rats 1810 rabbit down 19 
AC Wistar rats 1810 rabbit down 17 
NFATc4+MEF2c NVCM 6658 rat up 72 
"E-box mutations" Sol8 cells 1815 rabbit up 83 
GSK3β 
overexpression 
HEK293 1824 rabbit down 84 
none C2C12 1810 rabbit characterization 85 
PO Wistar rats 284 rabbit down 18 
Egr-1 and TPA NVCM 2577 human characterization 16 
none NVCM and C2C12 2577 human characterization 86 
Sp-1 cotransfection Sol8 cells 1810 rabbit up 87 
High glucose NVCM 600 rat down 76 
 
Table 1. Summary of literature describing effects of (cardiac) muscle signaling in SERCA2a promoter regulation. 
ET-1: Endothelin 1; AC: Aortic Constriction; LIF: Leukemia Inhibitory Factor; IL-6: Interleukin 6; T3: Thyroid 
hormone; MEF2c: Myocyte Enhancer Factor; ATF6:Activating Transcription Factor 6   ; PO: Pressure Overload; 
NFATc4: Nuclear factor of activated T-lymphocytes c4; GSK3β: Glycogen Synthase Kinase 3β; Egr-1: Early 
growth factor 1; TPA: 12-O-tetradecanoylphorbol 13-acetate   ; NVCM: Neonatal Ventricular Cardiomyocytes;  
   
1.10. In vivo regulation of the rat SERCA2a promoter  
Similar to studies of human heart failure, various murine models of pressure and volume 
overload have extensively described the reduction of SERCA2a activity, as well as 
SERCA2a’s protein and mRNA expression 6,69-71. Inhibitory effects of increased load on 
SERCA2a transcription regulation were also documented by studies that used the nuclear 
run-on assay or  in vivo injection of rabbit SERCA2a promoter-Luciferase constructs in rat 
hearts subjected to pressure 17,19,20. Using the latter technique, several load-responsive 
elements were identified located within the first –1800 bp of the rabbit SERCA2a promoter 
that contribute to the down-regulation of SERCA2a promoter activity following pressure 
overload 18. Homology searches revealed a high degree of similarity of the first 1500 bp 
upstream of the transcription initiation site of the rabbit and the rat SERCA2a promoter 
(Figure 5). However, more detailed analyzes of the rat and mouse SERCA2a promoter 
identified multiple conserved sequences to at least  –4100 bp 72, suggesting that the 
physiologically relevant length of the rat SERC2a promoter extends to approximately –4100 
bp. Previous studies using shorter (-1800 bp) deletion variants of the rat SERCA2a promoter 
might therefore have missed important regulatory cis-acting promoter boxes located in more 
up-stream regions 73.  
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1.11. Calcium, contraction and SERCA2a transcription in a model of cultured 
myocytes   
 Calcium and contractile activity are two important mediators in the development of 
pathological cardiac hypertrophy. The necessary coupling of calcium to contraction makes it 
impossible to investigate the effects of both mediators in SERCA2a promoter regulation 
separately. The experimental in vitro model of isolated, spontaneously contracting neonatal  
rat ventricular cardiomyocytes (NVCM) enables the study of the individual roles of calcium 
and contractile activity in transcription regulation of SERCA2a. NVCM were isolated from 2-3 
day old Wistar rats and three days after isolation these cardiomyocytes showed regular and 
reproducible spontaneous contractions 72. The model of cultured spontaneously contracting 
NVCM is commonly used as a model to describe pathological cardiac hypertrophy, as 
prohypertrophic stimuli can induce changes in mRNA and protein expression and protein 
phosphorylation analogous to the changes observed in in vivo models of pathological cardiac 
hypertrophy 16,74-78. To distinguish between the individual effects of calcium and contractile 
activity on SERCA2a gene expression and transcription regulation, the cross-bridge 
uncoupler 2,3-butanedione monoxime (BDM) was used to induce contractile arrest, while 
maintaining normal calcium transients 79. Furthermore, the L-type calcium channel blocker 
verapamil was used to block contraction as well as calcium transients which could affect 
SERCA2a gene expression 80. Using these blockers, separately or in combination, the roles 
of contraction and calcium in SERCA2a transcription and mRNA expression regulation were 
assessed.   
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1.12. Conclusions 
 Decreased SERCA2a mRNA and protein expression during pathological cardiac 
hypertrophy and cardiac failure have been described thoroughly. Impaired SERCA2a 
expression is likely to result from a repression of SERCA2a promoter activity. Effects of pro-
hypertrophic signaling pathways on SERCA2a expression or direct effects of pro-
hypertrophic transcription factors on SERCA2a promoter regulation are largely unexplored. 
This thesis therefore focused on the role of several of these pathways and their 
corresponding transcription factors involved in calcium and contractile activity mediated 
SERCA2a expression. Furthermore, this thesis characterizes the rat SERCA2a promoter.  
Objectives: 
I. In vitro analyses of load- and calcium-dependent signal transduction in the 
regulation of SERCA2a transcription and mRNA expression in rat 
cardiomyocytes. 
II. Characterization of load- and calcium-dependent regulatory factors involved in 
the regulation of SERCA2a transcription in rat cardiomyocytes. 
III.  In vivo assessment of load-dependent rat SERCA2a transcription regulation 
in the adult rat heart. 
 
The outline of this thesis is the following:  
Chapter two examines the effects of calcium-dependent signaling and contractile activity- 
dependent signaling in the regulation of SERCA2a transcription and mRNA expression. 
Chapter three investigates contractile activity-induced RhoA-ROCK-SRF signaling in 
SERCA2a promoter regulation. In Chapter four, effects of the GATA4 transcription factor 
and its regulating kinases in SERCA2a promoter regulation are described, and finally, in vivo 
analyses of SERCA2a transcription in overload-induced pathological cardiac hypertrophy are 
described in Chapter five. Chapter six discusses the results obtained in this PhD-study and 
new perspectives on SERCA2a transcription regulation are put forward.  
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2.1. Abstract 
 
Downregulation of sarco-endoplasmic reticulum calcium ATPase 2a (SERCA2a) expression is a 
critical marker of pathological myocardial hypertrophy. The effects of calcium-dependent 
signaling and of contractile activity on the regulation of myocardial SERCA2a expression remain 
unclear. The present study dissociates effects of calcium-dependent signaling through 
calcineurin (CN) and calmodulin dependent protein kinase-II (CAMK-II), from effects of 
contractile activity in spontaneously contracting rat neonatal ventricular cardiomyocytes (NVCM) 
using 2,3-butanedione monoxime (BDM), which arrests contractions but maintains calcium 
fluxes. SERCA2a mRNA expression was analyzed using Northern hybridisation in 
spontaneously contracting NVCM (control) and in NVCM treated with either BDM, L-type Ca2+-
channel blocker (verapamil), CN-blocker (cyclosporin A; CsA), CAMK-II blocker (KN-93), or 
combinations thereof. Transient transfection of the CN-dependent transcription factor nuclear 
factor of activated T-lymphocytes (NFATc), coupled to GFP, was used to detect NFAT nuclear 
translocation. The effects of CN/CAMK-II-dependent signaling were further dissected into effects 
of the transcription factors NFATc4 and myocyte enhancer factor 2c (MEF2c) on the activity of 
various SERCA2a promoter fragments using transient transfection assays.  Treatment with BDM 
induced a 2.5-fold rise in SERCA2a mRNA, which was abolished by addition of verapamil and 
was reduced by addition of CsA (-40%) and KN-93 (-20%). NFAT nuclear translocation was 
similar in control and BDM-treated NVCM. SERCA2a promoter activity was stimulated by 
NFATc4 and MEF2c, but only when both factors were co-transfected. Following contractile arrest 
with BDM, upregulation of SERCA2a mRNA expression by CN/CAMK-II signaling becomes 
evident. This upregulation is likely the result of synergistic stimulation of SERCA2a promoter 
activity by NFATc4 and MEF2c. Contractile activity opposes this upregulation through 
independent-pathways.                                     
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2.2. Introduction 
Cardiac hypertrophy occurs in response to a chronic increase in workload and is 
aimed at normalizing wall-stress. When unsuccessful, the initially adaptive hypertrophy will 
evolve to a pathological form characterized by changes in cardiac gene expression including 
downregulation of the sarco-endoplasmic reticulum calcium ATPase 2a (SERCA2a) protein 
level 1,2. This downregulation disturbs myocardial calcium handling and contributes to 
contractile dysfunction as evident from the improved contractility of hypertrophied 
myocardium following SERCA2a protein overexpression using transgenic approaches 3,4. 
The reduction of myocardial SERCA2a mRNA and protein expression in pathological 
hypertrophy was attributed to reduced SERCA2a promoter activity 5. This finding was further 
corroborated by lower activity of a -1800 bp SERCA2a promoter fragment when transfected 
in vivo in pressure-overloaded, hypertrophic hearts 6,7.  
Possible mediators of reduced SERCA2a expression in pressure overload-induced 
myocardial hypertrophy include calcium-dependent signaling pathways involving calcineurin 
(CN) and calmodulin-dependent protein kinase (CAMK) 8, as wells as calcium-independent 
signaling pathways directly linked to the increased mechanical stress 9. Stimulation of the 
calcium-dependent signaling pathways is considered to be important in the development of 
myocardial hypertrophy because of the demonstration of increased activity of CN and CAMK 
during pressure overload 10,11; because of the development of massive cardiac hypertrophy 
following cardiac-specific overexpression of CN or CAMK 12,13 and because of the ability of 
CN or CAMK blockers to inhibit development of hypertrophy both in vitro and in vivo 12,14,15.  
The CN and CAMK pathways modulate transcription through activation of the 
transcription factors NFAT (nuclear factor of activated T-lymphocytes) and MEF2 (myocyte 
enhancer factor 2), respectively. However, the effects of CN or CAMK signaling on 
SERCA2a expression remain unclear. In myocardial hypertrophy induced by CN 
overexpression, both a fall in SERCA2a mRNA 12 and a rise in SERCA2a protein 16 have 
been observed. Moreover, control of SERCA2a promoter activity by CN or CAMK signaling 
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has so far not been explored. It is similarly unclear what the role of mechanical activity is in 
the regulation of SERCA2a transcription.    
Here we investigated the effects of calcium-dependent signaling in the presence or 
absence of contractile activity on myocardial SERCA2a mRNA expression. Because of the 
obligatory linkage in the in vivo setting of calcium fluxes and contractile activity, their 
individual effects can only be explored in the in vitro setting. The present study therefore 
used spontaneously contracting neonatal ventricular cardiomyocytes (NVCM). Effects of 
calcium-dependent signaling were studied either following treatment of cells with 2,3-
butanedione monoxime (BDM), which maintains calcium fluxes but abolishes contraction, or 
following treatment with verapamil, which inhibits both calcium fluxes and contraction. 
Furthermore, transient transfection assays of NVCM were used to directly investigate 
transcriptional regulation of the SERCA2a promoter by NFATc4 and MEF2c. 
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2.3. Methods 
 
2.3.1 Cell culture of rat neonatal ventricular cardiomyocytes (NVCM) 
All animals were treated in accordance with the national guidelines of the Institutional 
Animal Care and Use Committee of the VU University Medical center. These guidelines 
conform with the Guide for the Care and Use of Laboratory animals published by the US 
National Institutes of Health (NIH Publication No.85-23, revised 1996). Neonatal ventricular 
myocytes were isolated from 2 or 3 day old Wistar rats (Harlan, Zwijndrecht, The 
Netherlands), essentially as described by Iwaki et al. 17. Pups were decapitated after CO2 
anaesthesia and hearts were quickly removed. The ventricles were digested by collagenase 
Type II (Worthington Biochemicals, Oosterzee, The Netherlands) and pancreatin. Ventricular 
myocytes were plated on 1% gelatine-coated dishes at a confluent density of 7x104 cells/cm2 
(day 0). Cells were plated for two days in DMEM containing 10% horse serum and 5% foetal 
bovine serum. At day three serum was replaced by DMEM containing 0.2% BSA. Starting at 
day four, medium was changed and supplemented with blockers. Cells were harvested at 
day seven. Medium, including blockers, was changed once at day five. Cells were allowed to 
contract spontaneously, were contraction arrested using verapamil (10µM) (Sigma, 
Zwijndrecht, The Netherlands), or were contraction arrested, while maintaining calcium fluxes 
using the cross-bridge uncoupler  BDM (7.5mM) (Sigma). The role of CN and CAMK-II in 
SERCA2a mRNA expression was investigated using the inhibitors cyclosporine A (CsA; 
1µM) (Calbiochem) and KN-93 (2µM), respectively (Sigma). Cells were kept in a humidified 
chamber with 5% CO2 at 37oC. 1-[β-D-arabinofuranosyl]cytosine (10 µM) was present from 
day three till day five; 1% penicillin /streptomycin were present in the media during the entire 
culture period.   
Chapter 2 
 
 
 
40
2.3.2. RNA isolation and Northern hybridisation 
Isolated total RNA (Tripure, Boehringer Mannheim) was separated on a 1.2% 
formaldehyde agarose gel (10 µg each sample; 40 V, 4.5 h). RNA was transferred by 
capillary flow onto Hybond-N-Membrane (Amersham), and crosslinked with ultraviolet 
radiation. Blots were pre-hybridised for one hour in  5x SSC (0.8 M NaCl, 0.08 M 
C6H5Na3O7*2H2O), 5x Denhardt’s  (100x Denhardt’s is 2 % ficoll, 2 % polyvinylpirrolidone, 2 
% BSA) 60 µg/ml sheared herring sperm DNA, 1% SDS, 50% formamide, after that a specific 
rat SERCA2a cDNA probe (1kb[PstI (+2624) to (polyA)+-tail]) was added. The probe was 
random prime labelled with [α-32P] dCTP (3000Ci/mmol) (Amersham) using the High Prime 
labelling kit (Roche). Blots were hybridised for approximately 16 hours and then washed to a 
stringency of 0.1x SSC+ 0.1% SDS at 42oC. Analysis was performed by phosphoimaging 
and messengers were quantified by the computer program Image Quant  (Bio-Rad). 
 
2.3.3. Preparation of plasmids for transfection 
Three SERCA2a promoter fragments with 5’-ends at -6588, -3263, -550 bp and 3’-
ends at +550 (+1 is the transcription initiation site) were cloned into a promoterless pGL3-
basic Luciferase vector (Promega, Madison, USA). CMV-pRL (Renilla) (Promega) was used 
for normalisation. Plasmids expressing constitutively active NFATc4, NFATc-GFP and wild 
type MEF2c were generous gifts from Dr. E. N. Olson 18.  
 
2.3.4. Sequence analysis of the rat SERCA 2a promoter 
The rat SERCA 2a promoter sequence was subcloned from a rat genomic P1 clone 
obtained from Genome systems Inc. (St. Louis, USA). The 5’-sequence of the SERCA2a 
gene (6588 bp) was sequenced on both strands by BaseClear (Leiden, The Netherlands). 
Using the Blast search program (http://www.ncbi.nlm.nih.gov/genome/seq/RnBlast.html), the 
promoter sequence was compared to the rat genome sequence and identified as the 
SERCA2a promoter. Furthermore, the 6588 bp SERCA2a fragment of the rat was compared 
to the SERCA2a promoter sequence of the mouse. Conserved regions in both promoters 
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were present up to -4100 bp upstream. Putative binding sites for the NFAT and MEF 
transcription factors were localized using the internet program CONSITE and TRANSFAC 
(http://mordor.cgb.ki.se/cgi-bin/CONSITE/consite?rm=t_input_single) 
 and http://transfac.mirror.edu.cn/TRANSFAC). 
 
2.3.5. Transient transfection assays 
Neonatal ventricular myocytes were transfected with Fugene (Roche, Almere, The 
Netherlands). SERCA2a Luciferase promoter constructs (250 ng) were transfected together 
with CMV-pRL plasmids (25 ng), with or without plasmids expressing constitutively active 
NFATc4 (1 µg), MEF2c (1 µg). Empty pOCAT plasmid was added to the transfection mix to 
equalise total DNA during transfection. Two days after transfection, cells were washed with 
phosphate buffered saline (PBS), harvested in 200 µl Luciferase lysis buffer (Promega, 
Madison, USA). Suspensions were spun down for two minutes at 10,000x g and the 
supernatant was used directly for analysis. Promoter activities were determined using the 
Dual Luciferase assay kit (Promega). Light signals were detected with a luminometer (Lumat 
LB 9507, Berthold, Bad Wildbad, Germany).  
For live-cell imaging experiments, spontaneously contracting NVCM were transfected 
with 1,5 µg NFATc-GFP. Twenty-four hours after transfection cells were either kept in 
medium containing 0.2 % BSA and contracted spontaneously, or were arrested using either 
BDM (7.5 mM; either with or without 1µM CsA), or verapamil (10 µM). Twenty-four hours 
after the addition of the blockers, the cells were analyzed for NFATc-GFP nuclear 
translocation. Nuclear localization of NFAT-GFP was confirmed by co-localization with 
Hoechst 33342 staining. Nuclear NFAT-GFP was quantified by measuring the sum of 
intensities, i.e., mean intensity of fluorescence times area in pixels, using SlidebookTM 
software as described under 2.6.                                                                                                                        
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2.3.6. Digital Imaging Microscopy 
All live-cell experiments were performed on a ZEISS Axiovert 200 MarianasTM 
inverted microscope (Intelligent Imaging Innovations, Denver, CO), equipped with a 
motorized stage (stepper-motor z-axis increments: 0.1 µm), and a turret of four epi-
fluorescence cubes (including DAPI, narrow-band GFP [Chroma Technology Co., 
Rockingham, VT] as well as a brightfield DIC cube). A cooled CCD camera (Cooke 
Sensicam [Cooke Co., Tonawanda, NY], 1280x1024 pixels) recorded images with true 16-bit 
capability. The camera is linear over its full dynamic range (up to intensities of over 4,000) 
while dark/background currents (estimated by the intensity outside the cells) are typically 
<100. Exposures, objective, montage and pixel binning were automatically recorded with 
each image stored in memory (Dell Dimension workstation: 1,7 GHz Xenon® dual processor, 
2GB RAM). The microscope, camera and all other hardware settings were controlled by 
SlidebookTM software (Slidebook version 4.0 [Intelligent Imaging Innovations, Denver, CO]). 
Microscopy was performed with a custom 10X air lens (ZEISS). The motorized filter turret 
allowed acquisition of one composite image on darkfield and brightfield within two seconds.  
 
2.3.7. Statistical analysis 
Data were expressed as means and evaluated using ANOVA with Bonferroni post-
hoc analysis. Differences were considered significant at p<0.05.  
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2.4. Results 
 
2.4.1. Effects of calcium fluxes and contractile activity on SERCA2a mRNA expression 
Total RNA was isolated from control (CTR) NVCM, which contracted spontaneously, 
from NVCM treated with BDM, which showed no contractile activity, from NVCM treated with 
verapamil, which also showed no contractile activity and from NVCM treated with either a 
CAMK-II inhibitor (KN-93) or with the CN-inhibitor CsA, which both maintained contractile 
activity. Only BDM treatment resulted in a significant 2.5-fold increase in SERCA2a mRNA 
expression (Figure 1a). KN-93 as well as CsA treatment induced a modest, non-significant 
decrease in SERCA2a mRNA expression (Figure 1a). In line with the load-induced 
expression of atrial natriuretic factor (ANF) 8,19, contractile arrest with either BDM or 
verapamil resulted in a 70 % decrease in ANF mRNA level (data not shown).  
Addition of verapamil to BDM-treated cells abolished the BDM-induced increase in 
SERCA2a mRNA (Figure 1b). The BDM-induced increase in SERCA2a mRNA was reduced 
by 20 % following addition of KN-93 and by 40 % following addition of CsA (Figure 1b), 
suggesting a CN/CAMK-II-dependent stimulation of SERCA2a expression in BDM-arrested 
NVCM. 
A B
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Figure 1 Representative autoradiograph of a SERCA2a and GAPDH Northern hybridization showing the effects 
of calcium signaling and contractile activity on SERCA2a mRNA expression. 
A: Upper panel: Total RNA (10 µg/lane) was size fractionated and hybridised with α32P-dCTP labelled probes for 
SERCA2a GAPDH mRNA. Lower panel: Arrest of contractile activity, but maintenance of calcium fluxes using 
(BDM) causes a 2.5- fold increase in SERCA2a mRNA expression, as compared to the spontaneously contracting 
NVCM (CTR). Treatment of NVCM with verapamil, CsA or KN-93 did not result in a change in SERCA2a mRNA 
expression. All blockers or combinations of blockers were added at four days after isolation and were present 
during three days. Data are presented as means ±  SEM of five independent experiments. †: p<0.001 vs. CTR. 
Abbreviations: CTR = control (spontaneous contractions), BDM = 2,3- butanedione monoxime, vera = verapamil, 
CsA = cyclosporine A. 
B: Upper panel: Representative autoradiograph of a SERCA2a and GAPDH Northern hybridization showing the 
involvement of calcineurin and CAMK-II in the 2.5-fold stimulation of SERCA2a mRNA expression. Lower panel: 
The 2.5-fold increase in SERCA2a mRNA expression, as observed in the mechanically unloaded cells (BDM), 
was abolished after addition of verapamil and could be partly (20 %) inhibited by the addition of KN-93, a CAMK-II 
inhibitor. Furthermore, addition of CsA to the BDM-treated cultures resulted in a 40 % inhibition. All blockers or 
combinations of blockers were added at four days after isolation and were present during three days. Data are 
presented as means ±  SEM of five independent experiments. †٭ p<0.001 vs. CTR † p<0.001 vs. BDM; ‡ p<0.05 
vs. BDM, ٭ p<0.001 vs. BDM.  
 
2.4.2. NFATc4/MEF2c signaling and SERCA2a promoter activity 
Various lengths of the rat SERCA2a promoter (-550 bp, -3263 bp and -6588 bp) 
driving expression of a Luciferase reporter gene were transfected either alone or in 
combination with plasmids expressing the transcription factors NFATc4 and/or MEF2c. The 
transcription activities of the different SERCA2a promoter lengths were unchanged after co-
transfection of either NFATc4 or MEF2c alone (Figure 2b-d). Co-transfection of both NFATc4 
and MEF2c resulted in a synergistic repression of the -550 bp and -3263 bp promoter 
fragments (Figure 2b,c) and a synergistic stimulation of the -6588 bp promoter fragment 
(Figure 2d). This synergistic stimulation supports the aforementioned CN/CAMK-dependent 
stimulation of SERCA2a mRNA expression.  
NFAT consensus sites were identified in all three SERCA2a promoter lengths, but 
MEF consensus sites were only identified in the -6588 bp promoter fragment. This finding 
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could underlie the synergistic stimulation by NFATc4 and MEF2c of the -6588 bp promoter 
fragment. To discern conserved regions of the SERCA2a promoter, the -6588 bp sequence 
was aligned with the same length of the 5’-SERCA2a promoter sequence of the mouse. This 
revealed extensive sequence homology up to -4100 bp (hatched boxes in Figure 2a). 
Notably, one MEF consensus site at position -3713 was fully conserved (Figure 2a). 
Conservation of this MEF site underscores its importance for the synergistic stimulation by 
NFATc4 and MEF2c of the SERCA2a promoter. 
 
 
 
 
 
 
Figure 2. Schematic linear representation of the various lengths of the SERCA2a promoter fragments that were 
cloned in the pGL3 Luciferase reporter plasmid. Panel A: Sequence analysis of the promoter revealed several 
NFAT concensus sites (N), and three MEF consensus sites (M). The M site indicated in bold, was fully conserved 
in both rat and mouse SERCA2a promoter. The complete rat promoter sequence was aligned both with the 
known rat as well as the mouse SERCA2a promoter sequence and showed high homology up to 4100 bp 
upstream (hatched boxes indicate >85 % sequence homology). 
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Figure 2 Effects of NFATc4 and MEF2c on SERCA2a promoter activity in NVCM cultures. Panel B-D: Plasmids 
containing 0.55 kb (B), 3.3 kb (C) and 6.6 kb (D) of the SERCA 2a promoter sequence, driving the Luciferase 
gene, were co-transfected with expression plasmids for either NFATc4 or MEF2c, or in combination. Luciferase 
activities were normalized to Renilla activities. The average basic activity of the three SERCA2a promoter 
fragments decreased with increasing length of the promoter sequence. The activity of the 6.6 kb fragment is 
approximately 60 % less active than the 0.55 kb fragment. Data are presented as means ±  SEM of six 
independent experiments. † p<0.01 vs. basal promoter activity; ‡ p<0.01 vs. NFAT co-transfection, ٭ p<0.01 vs. 
MEF co-transfection. 
 
2.4.3. NFAT translocation in NVCM cultures 
Spontaneously contracting NVCM were transfected with a NFATc-GFP expression 
plasmid to analyze nuclear translocation of NFAT under various conditions. Using digital 
imaging microscopy, the sum intensity, of nuclear GFP signals in CTR NVCM and in BDM-
treated NVCM were similar. There was, therefore, no evidence for contraction-induced 
inhibition of nuclear translocation of NFAT. Both verapamil and CsA treatments reduced 
nuclear translocation of NFAT, consistent with the calcium-calcineurin-NFAT signaling 
cascade (Figure 3). 
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Figure 3. Effect of contractile activity and calcium-dependent signaling on nuclear translocation of NFATc-GFP in 
NVCM. Upper panel: Representative life cell images of NVCM cultures transfected with an NFATc-GFP-
expression plasmid. BDM, CsA and verapamil were added 24 h after transfection and cells were analyzed 24 h 
later. Panels A-D show bright-field images with superimposed NFATc-GFP signal; panels E-G show NFAT-GFP 
signals only. Lower panel: Quantification of nuclear NFATc-GFP. The sum intensities of nuclear GFP-signal of 
eight different cells from three independent experiments are shown. Data are presented as means ±  SEM. † 
p<0.05 vs. BDM; ‡ p<0.05 vs. CTR. 
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2.5. Discussion 
 The present study on spontaneously contracting NVCM observes a CN/CAMK-II- 
dependent upregulation of SERCA2a mRNA expression which becomes evident following 
contractile arrest. Transient transfections of various lengths of the rat SERCA2a promoter 
suggest that the CN/CAMK-II-induced upregulation of SERCA2a mRNA expression results 
from synergistic stimulation of the SERCA2a promoter by NFATc4 and MEF2c. Life cell digital 
imaging microscopy shows similar NFAT nuclear translocation in spontaneously contracting 
and BDM-arrested cardiomyocytes, but lower NFAT nuclear translocation in verapamil-
arrested or CsA-treated cardiomyocytes. This suggests SERCA2a mRNA expression to be 
controlled by calcium and contractile activity through distinct and independent pathways, at 
least with respect to CN/NFAT signaling. 
 
2.5.1. Upregulation of SERCA2a mRNA expression by contractile arrest 
 Numerous studies revealed myocardial mechanical overload to reduce SERCA2a 
promoter activity and mRNA or protein expression 1,5-7,20 and this reduction of SERCA2a 
expression has become a marker for development of pathological hypertrophy during chronic 
mechanical overload. The spontaneously contracting NVCM used in the present study 
probably operated at an elevated mechanical load as they resisted deformation resulting 
from anchoring to the gelatine-coated dish and from simultaneously contracting neighbouring 
cells in the confluent culture, as also noted by others using this model 20,21. The increase in 
SERCA2a mRNA expression following contractile arrest of these cells with BDM is in line 
with the in vivo and in vitro analyzes describing load-dependent expression of SERCA2a 
1,6,7,20,21. Mechanical overload-induced repression of SERCA2a promoter activity has also 
been observed following in vivo myocardial transfection of a –1800 bp SERCA2a promoter 
fragment, which revealed significantly lower promoter activity in pressure-overload 
hypertrophy than in control hearts 6,7. The reverse, namely restored SERCA2a protein 
expression following mechanical unloading has recently been reported in end-stage human 
heart failure after insertion of a left ventricular assist device (LVAD) 22. The inhibitory effect of 
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mechanical load on SERCA2a promoter activity may result from the reduced contribution of 
load-dependent factors binding to cis-acting sites in the SERCA2a promoter, such as 
GATA4, NFkB and SRF, which are stimulated by PI3-kinase, reactive oxygen species and 
RhoA, respectively 23-25. Our data indicate that the putative load-dependent pathways do not 
interfere with the nuclear translocation of NFAT, as part of the CN/NFAT-dependent 
stimulation of SERCA2a expression (see below), since nuclear levels of NFAT were the 
same in contracting and BDM-arrested cells. However, interference of load-dependent 
pathways with events down-stream of activated CAMK can not be excluded based on our 
data.  
 
2.5.2. Stimulation of SERCA2a mRNA expression in arrested NVCM by Calcium 
 The role of calcium-dependent signaling in the regulation of myocardial SERCA2a 
expression is controversial. In CN overexpression-induced myocardial hypertrophy both a fall 
in SERCA2a mRNA 12 and a rise in SERCA2a protein were observed 16. Furthermore, control 
of SERCA2a promoter activity by CN/CAMK-II signaling has not been explored. The present 
study showed significant reductions in the elevated SERCA2a mRNA content of BDM-
arrested NVCM following administration of a CAMK-II inhibitor (KN-93) or of a CN inhibitor 
(CsA). In control NVCM, there was only a trend toward lower SERCA2a mRNA levels 
following administration of KN-93 or of CsA. This probably resulted from the contraction-
induced lowering of the SERCA2a level in the control NVCM, which rendered additional 
inhibitory effects less detecTable. Nevertheless, the current findings indicate calcium-
dependent signaling to result in upregulation of SERCA2a mRNA expression. Although a rise 
in SERCA2a mRNA expression is not necessarily related to a concomitant rise in protein 
expression 26, our data are consistent with the previously reported rise in SERCA2a protein 
in CN overexpression-induced myocardial hypertrophy 16, and also with the fall in SERCA2a 
protein observed in CsA-treated skeletal muscle 27. Moreover, the present observations are 
the first to document CAMK-II- induced upregulation of SERCA2a mRNA expression. This 
extends the role of CAMK-II signaling in myocardial hypertrophy 11,13,28 beyond its previously 
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reported actions on SERCA2a and phospholamban phosphorylation 29-31 to regulation of 
expression of SERCA2a. 
 The stimulatory effect of calcium-dependent signaling on SERCA2a mRNA 
expression was also analyzed at the SERCA2a promoter level using transient transfection 
assays. Various cis-acting sites have been described to be involved in stimulation (thyroid-
hormone response elements 32, MCAT, CarG, E-box 33) or inhibition (endoplasmic stress 
response elements 34, Sp-1 35, Egr-1 36) of SERCA2a promoter activity. However the present 
study focussed on the analyses of the effects of NFATc4 and MEF2c on various lengths (-
550 bp, -3263 bp and -6588 bp) of the SERCA2a promoter. Effects were only observed when 
both factors were present, showing inhibition of activity of both shorter fragments, which 
appears to be in agreement with the inhibitory effects of hypertrophic stimuli on the -1800 bp 
fragment of the SERCA2a promoter in vivo 6,7. The mechanism for suppressed activity of the 
shorter fragments by a combination of both factors but not by a single factor remains 
unresolved. Unexpectedly, a synergistic 3-fold stimulation in activity of the longest promoter 
fragment (-6588 bp) was observed. Similar synergistic or additive actions of NFAT and MEF 
have also been described for transcription of other genes 18,37. The stimulation of the -6588 
bp SERCA2a promoter by the combination of NFATc4 and MEF2c supports the observed 
calcium-dependent upregulation of SERCA2a mRNA expression. The stimulatory effect on 
the long fragment, but not on the -3263 bp fragment, is most likely related to the presence of 
consensus binding sequences for one or both factors in the sequence upstream of position -
3263. Sequence analysis indeed identified NFAT and MEF consensus sites at approximately 
-3500 bp (see Figure 2a). The importance of this region is supported by analysis of sequence 
homology of the rat and mouse SERCA2a 5'-sequences, which showed high homology up to 
-4100 bp, but not beyond. In particular, the MEF-site was fully conserved (see Figure 2a; 
indicated with M, written in bold). All previous studies addressing SERCA2a promoter activity 
with respect to hypertrophic signaling used promoter fragments of maximally 3200 bp in 
length 6,7,38. Results from these studies may therefore not show the full effect on SERCA2a 
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promoter activity, given the opposite response to CN/CAMK-signaling of such fragments 
compared to the longer promoter sequence (Figure 2a-d).  
  
2.5.3. Study limitations 
This in vitro study describes the stimulation of SERCA2a mRNA expression upon contractile 
arrest, with a potential role for NFATc4 and MEF2c as synergistic activators of SERCA2a 
transcription. However, the physiological role of this calcium-dependent stimulation of 
SERCA2a expression and the involvement of NFATc4 and MEF2c, especially in the context 
of an increased in vivo mechanical load, remains to be established. 
The observed reduction in SERCA2a gene expression following exposure to CsA or KN-93 
could have resulted from CsA or KN-93 mediated effects on calcium fluxes thereby indirectly 
affecting CN/CAMK-II pathway activity through an upstream mechanism. Upstream 
modulation of CN-NFAT signaling has recently been reported for cGMP-dependent protein 
kinase, which suppressed NFAT activation through reduction of L-type calcium channel 
activity 39. Effects of CsA or KN-93 on calcium fluxes have so far not been reported and 
therefore render such an upstream modulation unlikely. Furthermore, the use of the 
"chemical phosphatase" BDM as a cross-bridge uncoupler has certain limitations. Several 
studies describe that in addition to its effects on force generation, BDM modulates the activity 
of several proteins including the L-type calcium channel and gap junction channels, possibly 
due to dephosphorylation 40-42. These effects are however observed at higher concentrations 
of BDM (between 15-50 mM) than those required to inhibit contractile activity. The BDM 
concentration (7.5 mM) used in the present study is reported to maintain calcium transients 43 
which was confirmed by our own observations (A. Muller, unpublished results).     
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2.6. Conclusions 
 In contraction-arrested NVCM, calcium-dependent signaling stimulates SERCA2a 
transcription. Both CN and CAMK-II pathways are involved in the calcium-dependent 
upregulation, most likely due to synergistic stimulation of the SERCA2a promoter by NFATc4 
and MEF2c. Contractile activity and calcium-dependent signaling exert their actions on 
SERCA2a gene expression through distinct and independent pathways. Future studies 
should therefore address not only calcium-dependent but also mechanical-stress sensitive 
signaling by which contractile activity inhibits SERCA2a expression. 
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3.1. Abstract 
Altered SERCA2a transcription may underlie decreased SERCA2a expression that is 
observed during pathological cardiac hypertrophy. GATA4 is a transcription factor that may 
be involved in this process and binding sites for GATA4 have been identified in the first 3.2 
kb of the rat SERCA2a promoter. This study identified an additional site at -5625 bp. Effects 
of GATA4 on SERCA2a promoter activity as well as the involvement of GATA4 in load-
dependent SERCA2a promoter regulation were investigated in neonatal ventricular 
cardiomyocytes (NVCM). Transfection experiments showed that GATA4 stimulated the 
activity of the 6.6 kb rat SERCA2a promoter (+227%), whereas GATA4 reduced activity of 
the 3.2 kb SERCA2a promoter fragment (-37%). Previously, we identified a contractile arrest-
induced increase of SERCA2a mRNA expression in NVCM. The present study shows that in 
arrested NVCM, nuclear accumulation of GATA4 was increased by 38% compared to 
contracting NVCM. Furthermore, Western analyzes showed increased phospho-protein to 
total protein ratios of the GATA4 regulating kinase GSK-3β. This inactivation possibly 
underlies the accumulation of GATA4 in arrested NVCM. Inactivation of GSK3β in 
contracting NVCM by lithium chloride revealed a 79% stimulation of the 6.6 kb, but not of the 
3.2 kb SERCA2a promoter fragment. In conclusion, this study suggests a role for the -5625 
bp GATA4 site in the GATA4-dependent stimulation of SERCA2a transcription. Furthermore, 
evidence is provided for a prominent role for GSK3β in contractile arrest-induced nuclear 
accumulation of GATA4 that may contribute to the earlier observed rise in SERCA2a mRNA 
expression in arrested NVCM. 
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3.2. Introduction 
Overload-induced pathological myocardial hypertrophy is characterized by reduced 
sarco-endoplasmic reticulum calcium ATPase 2a (SERCA2a) mRNA and protein expression. 
Repression of SERCA2a promoter activity appears to be the principal cause of impaired 
SERCA2a function 1,2, resulting from altered activity of one or more transcription factors. 
Several lines of evidence suggest the involvement of factors such 3,4 as serum response 
factor (SRF), nuclear factor of activated T-lymphocytes (NFAT) and myocyte enhancer factor 
(MEF) in the control of SERCA2a promoter activity 5. A fourth factor implicated in the 
development of pathological hypertrophy is the cardiac-specific transcription factor GATA4. 
However, in contrast to SRF, NFAT and MEF, no data are available on the regulation of 
SERCA2a promoter activity by this factor.  
 Both in vivo and in vitro models of cardiac hypertrophy and failure have demonstrated 
that GATA4 is activated by elevated chronic workload 6-8, by humoral factors 9 and by stress-
induced signaling pathways, such as RhoA 10, p38 MAPK 11,12, ERK1-2 8,12,  and PI3-
kinase/Akt/ glycogen synthase kinase 3β (GSK3β) 13,14. Furthermore, as part of the PI3-
kinase pathway, GATA4 is suggested to be anti-apoptotic 15. GATA4 is identified as one of 
six GATA transcription isoforms. GATA4 is, like GATA5 and GATA6 involved in heart 
development, whereas GATA 1-3 are important in the development of hematopoietic stem 
cells 16. Each of the GATA isoforms recognizes the promoter consensus sequence (T/A) 
GATA (A/G), through a highly conserved region of two zinc fingers 16. Upon phosphorylation 
by ERK1/2, GATA4 translocates to the nucleus and binds to GATA4 responsive genes. In 
contrast, phosphorylation of GATA4 by GSK3β results in its nuclear export 14. Promoter 
regulation by GATA4 not only depends on phosphorylation but also on interaction of GATA4 
with other transcription factors. Stimulation of ANF promoter activity by GATA4 requires 
Nkx2.5 17. Stimulatory effects of GATA4 on gene transcription have also been demonstrated 
to require other pro-hypertrophic transcription factors, such as NFAT 18, SRF 19 and MEF 20. 
Promoter sequence analyzes revealed GATA responsive elements in both human and the rat 
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SERCA2a promoters 21, but as yet no studies have analyzed transcription regulation of 
SERCA2a by GATA4. 
The present study analyzed the 6.6 kb rat SERCA2a promoter for the presence of GATA4 
binding sites and investigated the role of GATA4 in the transcriptional control of this 
promoter. Direct effects of GATA4 on SERCA2a promoter regulation were assessed using 
transient transfection experiments in C2C12 skeletal myoblasts, COS7 kidney cells and 
spontaneously contracting NVCM. In the latter model, a 2.5-fold increase in SERCA2a 
mRNA expression was found following removal of workload by contactile arrest in a previous 
study. The calcium-dependent, pro-hypertrophic signaling pathways calcineurin 
(CN)/NFATc4 and calmodulin kinase II (CAMK-II)/MEF2c were shown to contribute to this 
stimulation of SERCA2a mRNA expression. To test the involvement of GATA4 in the load-
dependent repression of SERCA2a expression, activities of GATA4 regulating kinases such 
as Akt, GSK3β and ERK1/2 and nuclear accumulation of GATA4 and NFATc4 were 
evaluated in spontaneously contracting and contraction-arrested NVCM. 
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3.3. Methods 
3.3.1. Cell culture of NVCM, C2C12 mouse skeletal myoblasts and COS7 kidney cells  
 All animals were treated according to the national guidelines and with the permission 
of the Institutional Animal Care and Use Committee (IACUC) of the VU University Medical 
center, the Netherlands. Neonatal ventricular myocytes were isolated from 2 or 3 day old 
Wistar rats (Harlan, Zwijndrecht, The Netherlands). Pups were decapitated after CO2 
anesthesia and hearts were quickly removed. The ventricles were digested by collagenase 
Type II (Worthington Biochemicals, Oosterzee, The Netherlands) and pancreatin (Sigma, 
Zwijndrecht, The Netherlands). Ventricular myocytes were plated on 1 % gelatine-coated 
dishes at a confluent density of 7x104 cells/cm2. During the experimental protocol of three 
days, cells were cultured in DMEM (GIBCO BRL, Life technologies, Breda, The Netherlands) 
containing 0.2 % bovine serum albumin (BSA; Sigma, Zwijndrecht, The Netherlands) and 
penicillin /streptomycin (P/S) antibiotics (GIBCO BRL, Life Technologies, Breda, The 
Netherlands). Cells were kept in a humidified chamber with 5% CO2 at 37oC, and were 
allowed to contract spontaneously, or were mechanically unloaded, while maintaining 
calcium transients using the cross-bridge uncoupler 2, 3- butanedione monoxime (BDM; 7.5 
mM) (Sigma, Zwijndrecht, The Netherlands), as described previously. C2C12 mouse skeletal 
myoblasts and COS7 kidney cells were maintained in DMEM containing 10 % foetal bovine 
serum (FBS; GIBCO BRL, Life technologies, Breda, The Netherlands) and 1 % P/S.  
 
3.3.2. Preparations of plasmids 
 The SERCA2a promoter fragments with 5’-ends at -6588, and -3200 and 3’-ends at 
+550 (+1 is the transcription initiation site) were cloned into a promoterless pGL3-basic 
Luciferase vector (Promega, Leiden, The Netherlands), as described previously 22. The CMV-
pRL Renilla (Promega) was used for normalisation. The plasmid expressing full length 
GATA4 was a generous gift from Dr. M. van Bilsen. 
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3.3.3. Transient transfection assays 
NVCM, C2C12 skeletal myoblasts and COS7 kidney cells were transiently transfected 
with Fugene (Roche, Almere, The Netherlands). Luciferase reporter plasmids were driven by 
various deletion variants of the SERCA2a promoter (250 ng/10 cm2) and were transfected 
together with CMV-pRL plasmids (25 ng/10 cm2) to correct for transfection efficiency. COS7 
kidney cells and C2C12 skeletal myoblasts were used to investigate effects of non cardiac-
specific factors that could interfere with SERCA2a transcription regulation. SERCA2a 
promoter Luciferase reporters were transfected in the presence or absence of an expression 
plasmid encoding the GATA4 (1 µg/10 cm2) protein. Empty pOCAT plasmid was added to 
the transfection mixtures to equalise total DNA during transfection. Medium was changed 24 
hours after transfection and supplemented with blockers where appropriate. Two days after 
transfection, cells were washed with phosphate buffered saline (PBS), harvested in 200 µl 
Luciferase lysis buffer (Promega, Madison, USA). Suspensions were spun down for two 
minutes at 10,000x g and the supernatant was used directly for analysis. Promoter activities 
were determined using the Dual Luciferase assay kit (Promega, Madison, USA). Light 
signals were detected with a luminometer (Lumat LB 9507, Berthold, Bad Wildbad, 
Germany).  
 
3.3.4. Immunohistochemistry 
Spontaneously contracting NVCM, BDM-arrested NVCM and lithium chloride (LiCl; 10 
mM) treated NCVM, were washed in PBS at room temperature and fixed in 2 % para-
formaldehyde. Cells were permeabilized in ice-cold acetone/methanol (30 %/70 %) solution 
and after three wash steps in PBS (10 minutes each) cells were incubated for one hour with 
a primary rabbit anti-GATA4 (full length) antibody (Santa Cruz, Heidelberg, Germany; 1:200 
in PBS+1 % BSA), a primary rabbit-anti-NFATc4 antibody (Santa Cruz; 1:300 in PBS+1 % 
BSA). Cells were washed three times in PBS+0.1% Tween 20 and subsequently incubated 
with a secondary swine anti-rabbit antibody labelled with FITC (DAKO; Glostrup, Denmark; 
  GATA4-dependent control of SERCA2a transcription 
 
 
 
63
1:45 in PBS+1 % BSA), together with rhodamin-phalloidin (1:100), to stain F-actin sarcomere 
structures. Cells were finally washed three times in PBS+1 % Tween 20. DAPI nuclear stain 
was added to PBS. Bright-field microscopy was used to pick cells randomly and fluorescent 
microscopy was subsequently used to analyze cells for nuclear GATA4, NFATc4, and F-actin 
staining.  
 
3.3.5. Western blot analyzes 
Total protein was isolated from cells treated with different blockers using a 
commercial lysis buffer (BIOMOL, Hamburg, Germany; 25 mM Tris, 0.5 mM DTT, 50 µM 
EDTA, 50 µM EGTA, 0.1 % NP-40, pH 7.5 containing a cocktail of protease inhibitors). Total 
protein concentrations were determined using the BCA colorimetric protein assay kit (Pierce, 
Rockfort, USA).  Proteins were separated by SDS polyacrylamide gel electrophoresis (30 
minutes at 60 V followed by 50 min 180 V). The separating gel contained 8 % total 
acrylamide (acrylamide to bisacrylamide ratio 200:1; pH 9.3), while the stacking gel 
contained 3.5 % total acrylamide (acrylamide to bisacrylamide ratio 20:1; pH 6.8). Gels were 
blotted onto nitrocellulose membranes (90 minutes at 75 V). Membranes were stained 
overnight at 4oC with specific primary antibodies against total as well as phosphospecific 
isoforms of ERK1/2 (1:1000; New England Biolabs, Frankfurt am Main, Germany), Akt 
(1:1000; New England Biolabs), GSK3β (1:1000; Cell Signaling Technologies, Leusden, The 
Netherlands). Secondary antibodies coupled with horse radish peroxidase were incubated for 
one hour at room temperature. Protein expressions were visualized with a 
chemiluminiscence kit (Amersham Biosciences, Freiburg, Germany). Staining was quantified 
using a CCD camera (Fuji Science Imaging Systems) in combination with AIDA Image 
analyzer software (Isotopenmeßgeräte GmbH, Staubenhardt, Germany).  
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3.3.6. Statistical analysis 
Data were expressed as means and evaluated using either a Student t-test, or an 
ANOVA with Bonferroni or Dunnett post-hoc analysis. Differences were considered 
significant at p<0.05. 
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3.4. Results 
3.4.1. GATA4 and SERCA2a promoter regulation 
 The presence of GATA4 responsive elements in the SERCA2a promoter was 
assessed using the CONSITE program. Four 100 % consensus sites were identified, 
including an as yet unidentified site in the far upstream region of the SERCA2a promoter at 
position -5625 bp (Figure 1a). To analyze GATA4-dependent control of SERCA2a 
transcription, co-transfection experiments were performed with GATA4 and a 6.6 kb or 3.2 kb 
SERCA2a promoter fragment driving a Luciferase reporter gene. To identify contributions of 
(cardiac) muscle-specific factors in GATA4-dependent SERCA2a promoter regulation, 
transfection experiments performed in NVCM and C2C12 mouse skeletal myoblasts were 
compared to experiments performed in COS7 kidney cells.  
Co-transfection of GATA4 resulted in a 37 % decrease of pS2 (3.2) promoter activity 
in spontaneously contracting NVCM, whereas GATA4 enhanced the pS2 (6.6) promoter 
activity by 227 % (Figure 1b). This GATA4 dependent stimulation appeared to be muscle-
specific, as stimulatory effects of GATA4 were also identified in C2C12 cells (106 %), but not 
in COS7 kidney cells (Figure 1c).  
Figure 1a. Schematic representation of the rat SERCA2a promoter. Previous homology searches identified a high 
degree of similarity between the rat and mouse SERCA2a promoter up to position 4100 , as described elsewhere 
22. Using the CONSITE program, four GATA4 consensus sites were identified (G1-G4) at -1340 bp, -1956 bp, -
2681 bp, -5625 bp, respectively. To investigate control of the SERCA2a promoter by GATA4, the 6.6 kb rat 
SERCA2a promoter fragment was cloned in front of the Luciferase gene. A 3.2 kb deletion variant was generated 
to investigate the contribution of promoter regulatory elements located beyond -3.2 kb.  
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Figure 1b. Transient transfection experiments performed in spontaneously contracting NVCM. GATA4 repressed 
pS2 (3.2) (grey bars), whereas this factor stimulated pS2 (6.6) (black bars). Data are presented as means ± SEM. 
of at least six independent transfection experiments. CTR= Control. ‡  p <0.01 vs CTR. 
Figure 1c. Transient transfection experiments performed in C2C12 mouse skeletal myoblasts and in COS7 kidney 
cells. To investigate control of the SERCA2a 6.6 kb promoter fragment by the GATA4 transcription factor, the pS2 
(6.6) Luciferase reporter plasmid was co-transfected in the presence or absence of the expression plasmid 
encoding the total GATA4 protein. In C2C12 myoblasts, GATA4 stimulated pS2 (6.6) promoter activity (grey bars), 
similar to that of observed in NVCM, whereas in COS7 cells GATA4 did not alter pS2 (6.6) activity (black bars). 
Data are presented as means ± SEM. of at least six independent transfection experiments. CTR= Control. † p 
<0.01 vs CTR. 
 
3.4.2. Contractile arrest and nuclear accumulation of GATA4 and NFATc4 
To test the possible involvement of endogenous GATA4 in the regulation of 
SERCA2a expression by contractile activity, nuclear GATA4 was assessed in contracting 
and in contraction-arrested NVCM. Immunohistochemical analyzes revealed a 38 % increase 
of nuclear accumulation of GATA4 (Figure 2A, Panels A and B) following contractile arrest.  
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Figure 2a.  Immunohistochemical analyzes of nuclear GATA4 (A, B) and NFATc4 (C, D) in spontaneously 
contracting NVCM (A, C) and contraction-arrested NVCM (B, D). Nuclear GATA4 is increased under conditions of 
contraction arrest, as shown in Figure 2B. Nuclear NFATc4 translocates to the nucleus following contraction 
arrest. Figure 2b. Sum intensities of nuclear GATA-4 of at least 30 cells from three independent experiments are 
shown. Data are presented as means ± SEM. CTR: Control, spontaneously contracting NVCM; BDM: 2, 3-
butanedione monoxime. †  p <0.05 vs. Control. 
 
Next, the phosphorylation status of ERK1/2 and GSK3β, two GATA4 regulating 
kinases were determined in contracting and contraction-arrested NVCM. The activation 
status of these kinases was inferred from the ratio of phosporylated protein to total protein 
expression. Previous reports demonstrated ERK1/2 to be able to increase nuclear 
accumulation of GATA4 8,12-14. In the present study, however, three days of contractile arrest 
reduced the ratio of phosphorylated ERK1/2 to total ERK1/2 (Figure 3A), indicating that 
ERK1/2 is not involved in the increased nuclear accumulation of GATA4 in contraction-
arrested cells. However, the ratio of phosphorylated GSK3β to total GSK3β expression was 
increased following contractile arrest (Figure 3B). This higher phosphorylation status of 
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GSK3β will correspond to lower activity of the kinase and may thus explain the accumulation 
of GATA4 in the nucleus of contraction arrested NVCM. Surprisingly, Western blot analyzes 
revealed impaired signaling via Akt, an upstream regulator of GSK3β activity (Figure 3C), 
indicating that inactivation of GSK3β most likely results from enhanced kinase activity that is 
distinct from Akt signaling. Since GSK3β is involved in regulation of nuclear translocation of 
both GATA4 and NFATc4, nuclear levels of NFATc4 were next determined using 
immunohistochemistry. Parallel to increased nuclear accumulation of GATA4 following 
contractile arrest, nuclear NFATc4 was also increased (Figure 2A, Panels C and D). The 
concordant increase in nuclear accumulation of both transcription factors following contractile 
arrest renders involvement of a decreased activation status of GSK3β likely.  
 
Figure 3. Results of Western Blot analyzes. 
Panel A: Western blot analyzes of ERK1/2. 
Total protein was isolated from three 
different cultures of spontaneously 
contracting NVCM (first three lanes) and 
from three different cultures of contraction-
arrested NVCM (last three lanes). Three 
days of contractile-arrest, attenuated the 
phosphorylation of ERK1/2(Thr202-Tyr204), and reduced the ratio of phosphorylated ERK1/2 to total ERK1/2. 
Panel B: Western blot analyzes of GSK3β. Total protein was isolated from two different cultures of spontaneously 
contracting NVCM (first two lanes) and from two different cultures of contraction-arrested NVCM (last two lanes). 
Phosphorylation of GSK3β (Ser9) was unaffected in both cell cultures, whereas total GSK3β expression was 
reduced in contraction-arrested cultures. Panel C: Western blot analyzes of Akt. Total protein was isolated from 
three different cultures of spontaneously contracting NVCM (first three lanes) and from three different cultures of 
contraction-arrested NVCM (last three lanes). Three days of contractile-arrest, attenuated the phosphorylation of 
Akt (Ser473) and reduced the ratio of phosphorylated Akt to total Akt. 
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3.4.3. GSK3β inhibition and SERCA2a transcription regulation 
To further explore involvement of GSK3β in SERCA2a regulation, lithium chloride 
(LiCl) was used to inhibit GSK3β activity. Administration of LiCl to spontaneously contracting 
NVCM was expected to replicate the contractile arrest-induced enhancement of SERCA2a 
promoter activity by GATA4. This enhancement was indeed observed, as evident from a 
76% stimulation of pS2 (6.6 kb) promoter activity (Figure 4a). Similarly, stimulation of pANF 
promoter activity (117 %) was also manifest after administration of LiCl to spontaneously 
contracting NVCM (Figure 4b). Inhibition of GSK3β by LiCl did not alter activity of the pS2 
(3.2 kb) deletion variant (Figure 4c), again emphasizing the importance of the GATA4 
responsive elements located beyond 3.2 kb. The dissimilar effect of LiCl on the 3.2 kb and 
6.6 kb pS2 promoters is consistent with the divergent response of both pS2 promoter lengths 
to stimulation by GATA4 (Figure 1b) and emphasizes the importance of the GATA4 
responsive element located beyond 3.2 kb in mediating GATA4 dependent stimulation of 
SERCA2a promoter activity. Since inhibition of GSK3β affects both GATA4 and NFATc4 30 
nuclear accumulation, NFATc4 may also have contributed to the stimulation of SERCA2a 
promoter activity by LiCl-mediated GSK3β inhibition.  
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Figure 4.  Results of transient transfection experiments in spontaneously contracting NVCM. Panel A: NVCM 
were transfected with Luciferase reporter plasmids driven by the pS2 (6.6). 24 h after transfection, medium was 
changed in medium with or without the GSK3β inhibitor LiCl (10 mM). LiCl-treatment resulted in a 79 % 
stimulation of pS2 (6.6) activity. Panel B: NVCM were transfected with Luciferase reporter plasmids driven by the 
ANF promoter (pANF). 24 h after transfection, medium was changed in medium with or without the GSK3β 
inhibitor LiCl (10 mM). LiCl-treatment resulted in a 117 % stimulation of pANF activity. Panel C: NVCM were 
transfected with Luciferase reporter plasmids driven by the 3.2 kb SERCA2a promoter fragment, pS2 (3.2). 24 h 
after transfection, medium was changed in medium with or without the GSK3β inhibitor LiCl (10 mM). LiCl-
treatment did not alter control of pS2 (3.2) activity. Data are presented as means ± SEM. CTR: Control, 
spontaneously contracting NVCM; LiCl: Lithium chloride; † p<0.01 vs. CTR. 
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3.5. Discussion  
Contractile arrest of neonatal ventricular cardiomyocytes (NVCM) has previously 
been demonstrated to increase SERCA2a mRNA expression. This rise in SERCA2a 
expression was ascribed to synergistic stimulation of SERCA2a promoter activity by NFATc4 
and MEF2c, the downstream transcription factors of the calcium-dependent CN and CAMK-II 
pathways 22. The current study shows that the stress-inducible transcription factor GATA4 
may also contribute to the rise of SERCA2a promoter activity following contractile arrest of 
NVCM, as suggested by the increased SERCA2a promoter activity induced by GATA4 and 
the enhanced nuclear translocation of GATA4 in contraction-arrested NVCM. This enhanced 
nuclear translocation of GATA4 in arrested NVCM is likely mediated by inactivation of 
GSK3β. Since inactivation of GSK3β also led to a parallel increase in nuclear accumulation 
of NFATc4, GSK3β-related effects may be the result of other stimulatory routes converging 
on the SERCA2a promoter 22. 
 
3.5.1. GATA4 and SERCA2a transcription 
 Sequence analyzes of the SERCA2a promoter revealed four 5’-WGATAR-3’ GATA4 
binding consensus sites (Figure 1a). To investigate the relative contribution of these 
consensus sites to the control of SERCA2a promoter activity by GATA4, transient 
transfection analyzes of deletion variants of the SERCA2a promoter driving the Luciferase 
gene were performed. To demonstrate cardiac specific control by GATA4, experiments were 
not only performed in spontaneously contracting NVCM, but also in C2C12 skeletal myoblasts 
and in COS7 kidney cells. Previous studies described control of rat or rabbit SERCA2a 
promoter fragments 23-27 shorter than the 6.6 kb promoter fragment used in the present study. 
Sequence homology of the rat and mouse SERCA2a promoter however suggests that the 
physiologically relevant length of the murine SERCA2a promoter (4.1 kb) exceeds the 
commonly used 3.2 kb promoter length 22, implying that important regulatory regions located 
beyond 3.2 kb in the SERCA2a promoter might therefore have been missed in previous 
studies investigating control of SERCA2a promoter activity. The present study suggests the 
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potential importance of regions beyond 3.2 kb of the rat SERCA2a promoter, as co-
transfection of GATA4 was demonstrated to result in a repression (-37%) of the 3.2 kb 
SERCA2a promoter fragment, but in a muscle-specific stimulation of the 6.6 kb SERCA2a 
promoter fragment. These observations imply a dual regulatory mechanism of GATA4 in 
SERCA2a transcription, which depends on the length of the promoter and on the association 
with different (cardiac) muscle specific factors.  
 
3.5.2. Contractile-arrest and GATA4 regulating kinases 
Following three days of contractile arrest, the ratio of phosphorylated ERK1/2 to total 
ERK1/2 was reduced as compared to contracting NVCM, which is in accordance with the 
increased ERK1/2 phosphorylation by enhanced mechanical load, as described in other 
studies 28;29. Contrastingly, the ratio of phosphorylated GSK3β to total GSK3β expression 
was increased under conditions of contractile arrest. This implies lower activity of GSK3β, 
resulting in reduced nuclear export of NFATc4 and GATA4, which is consistent with 
increased nuclear accumulation of NFAT and GATA4 in contraction-arrested NVCM. Since 
Akt activation was reduced in contraction-arrested NVCM and since GSK3β is located 
downstream of Akt, a fall in phosphorylation of GSK3β following contractile-arrest was 
expected. The observed rise in phosphorylation of GSK3β therefore implies that another 
kinase distinct from Akt augmented phosphorylation of GSK3β following contractile arrest 
(Figure 5). Nuclear accumulation of both GATA4 and NFAT confirms previous reports 
describing transcriptional control by GSK3β 30 and suggests that GSK3β can exert control on 
SERCA2a promoter activity through modulation of different transcription factors.  
 
 3.5.3. SERCA2a transcription and the interplay between GSK3β, GATA4 and NFATc4  
 Active GSK3β has previously been shown to decrease nuclear accumulation of both 
NFAT and GATA4 30 and to impair SERCA2a mRNA expression 31. The present study shows 
contractile arrest to decrease activation of GSK3β and to increase GATA4 nuclear 
accumulation as compared to contracting NVCM. If inactive GSK3β mediates the effects of 
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contractile arrest on SERCA2a transcription, these effects were expected to be reproduced 
by administration of LiCl, which inactivates GSK3β. Administration of LiCl 32 to contracting 
NVCM did not repress contractile activity and indeed resulted in a 79 % increase in the 
activity of the 6.6 kb SERCA2a promoter fragment. This stimulation is likely mediated by 
GATA4 since only co-transfection of GATA4 is able to increase SERCA2a promoter activity, 
whereas co-transfection of NFATc4 alone does not affect SERCA2a transcription, as 
previously demonstrated 22. Nevertheless, a potential contribution of NFATc4 in the LiCl-
induced stimulation of SERCA2a promoter activity can not be excluded because NFATc4 
can stimulate SERCA2a transcription through an obligatory interaction with MEF2c, as 
reported earlier 22. It may be hypothesized that, parallel to GSK3β inactivation, MEF2c 
nuclear accumulation is enhanced in contraction-arrested NVCM compared to contracting 
NVCM through factors other than CAMK-II. This, in combination with enhanced nuclear 
accumulation of NFATc4 following inactivation of GSK3β, would result in enhanced 
SERCA2a transcription. 
Whereas an earlier study already described stimulatory effects of NFATc4 and MEF2c on 
SERCA2a transcription and mRNA expression 22, the present study identifies GATA4 as an 
additional stimulator of SERCA2a transcription. Impaired GSK3β activity is a mechanism that 
may underlie enhanced SERCA2a mRNA expression induced by contractile arrest, via 
impaired nuclear export of GATA4 and NFATc4. These results therefore suggest that during 
pathological cardiac hypertrophy, increased nuclear activity of a subset of transcription 
factors, such as NFATc4, MEF2c and GATA4 may favour SERCA2a transcription in an 
attempt to increase its expression. However, this stimulation is apparently countered by other 
factors that are induced in parallel with contractile activity-dependent factors that ultimately 
lead to reduced SERCA2a expression. We therefore postulate that a critical balance 
between negative and positive regulators of nuclear NFAT, MEF and GATA4 will set levels of 
SERCA2a transcription (Figure 5).  
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Figure 5. Overview of the results obtained in this study. Contractile-arrest of NVCM results in an inactivation of 
GSK3β. Inactivation of GSK3β following contractile-arrest contributes to nuclear accumulation GATA4 and 
NFATc4. Nuclear GATA4 is able to stimulate SERCA2a promoter activity, as evident from direct co-transfection of 
GATA4. Inactivation of GSK3β following LiCl-treatment results in (GATA4-dependent) stimulation of pS2 (6.6). As 
demonstrated in a previous study, the nuclear accumulation of NFATc4 could also stimulate SERCA2a promoter 
activity in the presence of MEF2c. 
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4.1. Abstract 
In neonatal ventricular cardiomyocytes (NVCM) increased contractile activity inhibits sarco-
endoplasmic reticulum Ca2+-ATPase 2a (SERCA2a) expression and stimulates atrial 
natriuretic factor (ANF) expression, analogous to in vivo myocardial overload. This study 
investigated in NVCM involvement of  RhoA-ROCK-serum response factor (SRF) signaling in 
the regulation of SERCA2a and ANF gene transcription by contractile activity.  
Using immunohistochemistry and Western blot analyzes, RhoA and SRF expression was 
determined in contracting and contraction-arrested NVCM in the absence or presence of the 
ROCK inhibitor Y-27632. NVCM and COS7 kidney cells  were also transfected with reporter 
plasmids driven by the SERCA2a (pS2) or the ANF promoter (pANF).  
Contractile arrest of NVCM reduced total RhoA expression, limited its distribution to peri-
nuclear regions and reduced nuclear SRF (-39%), as did treatment of contracting NVCM with 
Y-27632 (-12%). Treatment with Y-27632 increased pS2 activity (+80 %) and decreased 
pANF activity (-41 %). In COS7 cells, pANF activity was only stimulated by a combination of 
cotransfected SRF and myocardin (+620 %), but the same combination failed to alter pS2 
activity. Control by SRF of pS2 activity was further assessed in COS7 kidney cells cultured in 
serum-containing medium. Under these conditions, SRF lowered pS2 activity (-23%). This 
implied the presence of a serum-dependent co-factor necessary for SRF to regulate pS2 
activity. 
This study demonstrates that contractile activity stimulates ANF and represses SERCA2a 
transcription via the RhoA-ROCK-SRF cascade. SRF stimulates ANF transcription in the 
presence of myocardin and represses SERCA2a transcription through an as yet unidentified 
cofactor. 
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4.2. Introduction 
Workload-induced pathological cardiac hypertrophy is associated with altered 
expression of a subset of genes, including increased expression of atrial natriuretic factor 
(ANF) and reduced expression of sarcoplasmic reticulum Ca2+-ATPase 2a (SERCA2a) 1. The 
downregulation of SERCA2a affects calcium handling and contractile function and may 
further contribute to the progression of pathological cardiac hypertrophy. This inverse 
regulation of SERCA2a and ANF is observed in various in vitro studies describing the effect 
of enhanced contractile activity 2,3 or contractile arrest 4,5. Moreover, in vivo unloading of the 
heart by left ventricular assist devices (LVAD) has also been shown to increase SERCA2a 
expression while reducing ANF expression 6,7. The transcriptional control mechanisms of this 
opposite regulation of SERCA2a and ANF expression remain largely unexplored.   
 Regarding regulation of SERCA2a transcription, there is controversy about the effects 
of various pro-hypertrophic signaling pathways. For instance, the calcium-dependent CAMK-
II/MEF2c and calcineurin/NFATc4 pathways are suggested to down-regulate SERCA2a 
expression 8, whereas a recent in vitro study demonstrated  a stimulation of SERCA2a 
promoter activity by NFATc4 and MEF2c, which was countered by contractile activity 5. The 
mechanism of this contraction-induced inhibition was unclear. In contrast to SERCA2a 
transcription, the direct effects of increased mechanical load (in vivo) or increased contractile 
activity (in vitro) on ANF transcription have been characterized in more detail. A principal 
pathway in the load-induced ANF transcription involves the small GTPase RhoA and its 
downstream effectors ROCK and serum-response factor (SRF) 9. RhoA is involved in actin 
dynamics regulation 10,11, as well as in contraction-mediated signal-transduction 2,12. RhoA 
can directly phosphorylate proteins involved in excitation-contraction coupling 13,14, or alter 
gene transcription through nuclear translocation of RhoA-dependent transcription factors, 
such as SRF 15. SRF is a 67 kDa phosphoprotein that belongs to the MCM1, Agamous, 
Deficiens and SRF (MADS) family of transcription factors and that binds to serum response 
elements (SRE; CC (A/T)6 GG) located in SRF-responsive promoters 16. In contrast to the 
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stimulatory action of SRF, a 32 kDa SRF splice variant can function as an inhibitory factor of 
transcription 17,18. Furthermore, transcriptional regulation by SRF can be modified through 
association with cell-specific co-factors, like the smooth-muscle factors Yin-Yang 1 19 and 
Mal 10, or the cardiac-specific factor myocardin 20. The latter has recently been reported to be 
up-regulated during heart failure 21. Examples of SRF-regulated muscle genes are α-actin 19 
and sodium calcium exchanger (NCX) 22.  The ANF promoter also contains SRE’s, through 
which RhoA-dependent signalling affects ANF transcription 9. Involvement of SRF in the 
regulation of both ANF and SERCA2a transcription was shown in a study by Zhang et al. 23 
in which cardiac-specific overexpression of SRF induced cardiomyopathy with a concomitant 
inhibition of SERCA2a expression and enhancement of ANF expression. 
 In the present study we assessed the possible role of the RhoA/SRF signalling 
pathway in the contraction-dependent, reciprocal regulation of SERCA2a and ANF promoter 
activity. Using an in vitro model of contracting and quiescent NVCM 5, cellular RhoA and SRF 
distribution, as well as transcriptional activity and contribution of SRF splice variants were 
determined. In addition, SERCA2a and ANF transcripition regulation by SRF and its co-factor 
myocardin was examined in more detail in transfection studies using COS7 kidney cells.   
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4.3. Methods 
 
4.3.1. Cell culture of NVCM and COS7 kidney cells  
All animals were treated according to the national guidelines and with the permission of the 
Institutional Animal Care and Use Committee (IACUC) of the VU University Medical center, 
the Netherlands. Neonatal ventricular myocytes were isolated from 2 or 3 day old Wistar rats 
(Harlan, Zwijndrecht, The Netherlands). Pups were decapitated after CO2 anaesthesia and 
hearts were quickly removed. The ventricles were digested by collagenase Type II 
(Worthington Biochemicals, Oosterzee, The Netherlands) and pancreatin (Sigma, 
Zwijndrecht, The Netherlands). Ventricular myocytes were plated on 1 % gelatine-coated 
dishes at a confluent density of 7x104 cells/cm2 and were cultured in DMEM containing 10 % 
horse serum and 5 % foetal bovine serum and 1 % penicillin /streptomycin (P/S) antibiotics. 
Three days after isolation serum components in the medium were replaced for 0.2 % bovine 
serum albumin (BSA) (all obtained from GIBCO BRL, Life Technologies, Breda, The 
Netherlands) as described previously 5. Four days after isolation, experiments were started. 
During the experimental protocol of three days, cells were cultured in DMEM containing 0.2 
% BSA and penicillin /streptomycin (P/S) antibiotics. Cells were kept in a humidified chamber 
with 5 % CO2 at 37oC, and were allowed to contract spontaneously, or were mechanically 
unloaded, while maintaining normal calcium transients using the cross-bridge uncoupler 2, 3-
butanedione monoxime (7.5 mmol/l) (Sigma, Zwijndrecht, The Netherlands). The role of 
RhoA/ROCK-SRF signaling in SERCA2a and ANF promoter activity was investigated using 
the ROCK-inhibitor Y-27632 (10 µmol/l) (Tocris; Avonmouth, UK). COS7 kidney cells were 
maintained in DMEM containing 10 % foetal bovine serum (FBS) and 1 % P/S. During the 
transfection protocol, COS7 kidney cells were cultured in DMEM containing 0.2 % BSA and 1 
% P/S and 24 h after transfection the medium was changed to DMEM containing 1 % P/S 
and either 10 % foetal bovine serum (FBS) or 0.2 % BSA. 
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4.3.2. Preparations of plasmids 
 The SERCA2a promoter fragment with 5’-ends at –6588 and 3’-ends at +550 (+1 is 
the transcription initiation site) was cloned into a promoterless pGL3-basic Luciferase vector 
(Promega, Madison, USA), as described previously 5. CMV-pRL (Renilla) (Promega, 
Madison, USA) was used for normalisation. The plasmid expressing full length SRF (pSRF) 
was a generous gift from Dr. R. Prywes and the plasmid expressing full length myocardin 
(pMyocardin) was a generous gift from Dr. Parmacek. The pANF (638) promoter-Luciferase 
reporter plamid was a generous gift from Dr. M. van Bilsen. The SRE cis-reporter construct 
(pSRE) was obtained from Stratagene (La Jolla, USA). 
 
4.3.3. Transient transfection assay 
NVCM (four days after isolation) and COS7 kidney cells were transiently transfected using 
the Fugene reagens (Roche, Almere, The Netherlands). Luciferase reporter plasmids driven 
by either a minimal promoter containing 5 tandem repeats of SRE boxes (1 µg/10 cm2), 
driven by the SERCA2a promoter (250 ng/10 cm2), or driven by the ANF promoter (1 µg/10 
cm2) were transfected together with CMV-pRL plasmids (25 ng/10 cm2), to normalize 
transfection efficiencies. To avoid the interaction with other cardiac specific factors, COS7 
kidney cells were used to elucidate the role of SRF and myocardin in ANF and SERCA2a 
promoter regulation. Empty pOCAT plasmid was added to the transfection mixtures to 
equalise total DNA during transfection. 24 hours after transfection medium was changed and 
supplemented with blockers where appropriate. Two days after transfection, cells were 
washed with phosphate buffered saline (PBS; 8 g/l NaCl, 0.2 g/l KCl, 1.44 g/l Na2HPO4, 0.24 
g/l KH2PO4; pH 7.4), harvested in 200 µl Luciferase lysis buffer (Promega, Madison, USA). 
Suspensions were spun down for two minutes at 10,000x g and the supernatant was used 
directly for analysis. Promoter activities were determined using the Dual Luciferase assay kit 
(Promega, Madison, USA). Light signals were detected with a luminometer (Lumat 9507, 
Berthold, Bad Wildbad, Germany).  
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4.3.4. Immunohistochemistry 
 NVCM (non-treated and therefore spontaneously contracting, BDM-arrested, or Y-
27632 treated) were washed in PBS at room temperature and fixed in 2 % para-
formaldehyde. Cells were permeabilized in ice-cold acetone/methanol (30 %/70 %) solution 
and after three wash steps in PBS (10 minutes each) cells were incubated with a primary 
rabbit anti-SRF (full length) antibody (Santa Cruz; 1:100 in PBS+1 % BSA), or a primary 
rabbit-anti-RhoA antibody (Santa Cruz; 1:100 in PBS+1 % BSA) for one hour. Cells were 
washed three times in PBS+0.1 % Tween 20 and subsequently incubated with a cocktail of a 
secondary swine anti-rabbit antibody labelled with FITC (DAKO; 1:45 in PBS+1 % BSA), 
together with  rhodamin-phalloidin (1:100), to stain for F-actin filaments. Cells were finally 
washed three times in PBS+1 % Tween 20. DAPI nuclear stain was added to PBS. Using 
fluorescent microscopy, cells were analyzed for nuclear SRF, actin filaments or for total 
RhoA protein under the different culture conditions. 
 
4.3.5. Western blot analyzes 
 Total protein was isolated from cell treated with different blockers using a commercial 
lysis buffer (BIOMOL, Hamburg, Germany; 25 mM Tris, 0.5 mM DTT, 50 µM EDTA, 50 µM 
EGTA, 0.1 % NP-40, pH 7.5 containing a cocktail of protease inhibitors). Total protein 
concentrations were determined using the BCA colorimetric protein assay kit (Pierce, 
Rockfort, USA).  Proteins were separated by SDS polyacrylamide gel electrophoresis (20 
minutes at 60 V followed by 50 min 180 V). The separating gel contained 12 % total 
acrylamide (acrylamide to bisacrylamide ratio 200:1; pH 9.3), while the stacking gel 
contained 3.5 % total acrylamide (acrylamide to bisacrylamide ratio 20:1; pH 6.8). Gels were 
blotted onto nitrocellulose membranes (90 minutes at 400 mA). Membranes were stained 
overnight at 4oC with specific primary antibody against total RhoA (1:1000; Cytoskeleton, 
Denver, USA). Secondary mouse anti human antibody (1:1000) coupled with horse radish 
peroxidase were incubated for one hour at room temperature. Protein expressions were 
visualized with a chemiluminiscence kit (Amersham Biosciences, Freiburg, Germany). 
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Staining was quantified using a CCD camera (Fuji Science Imaging Systems) in combination 
with AIDA Image analyzer software (Isotopenmeßgeräte GmbH, Staubenhardt, Germany).  
 
4.3.6. Identification of SRF splice variants 
 To detect SRF splice variants in contracting or BDM-treated NVCM, that could 
contribute in the contraction-mediated down-regulation of SERCA2a mRNA expression, total 
RNA was reverse transcribed to cDNA. cDNA was incubated with specific SRF primers. 
These rat-specific SRF primers were developed after an extensive blast search 
(http://www.ncbi.nlm.nih.gov/blast.html) in which the rat SRF locus was identified on 
chromosome 9q12, immediately upstream of the PTK7-like gene. The generated SRF 
primers were slightly modified from the human SRF primers used in the study of Davis and 
colleagues (altered nucleotides are underlined and written in bold). The sense primer was 
located in exon 2 (5’-CTACCAGGTGTCGGAGTCTGA- 3’), and the anti-sense primer was 
located in exon 6 (5’-CAGACGGTGCTGTGAGGAACA-3’). The PCR reaction was performed 
as described by Davis et al. 18.  
 
4.3.7. Statistical analysis 
 Data are expressed as means and were evaluated using either a student T-test, or an 
ANOVA with Bonferroni post-hoc analysis. Differences were considered significant at p<0.05. 
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4.4. Results 
4.4.1. Contractile-arrest and RhoA  
NVCM were cultured for three days in DMEM containing 0.2 % BSA and either 
contracted spontaneously or were contraction-arrested by addition of the cross-bridge 
uncoupler BDM. Cells were fixed and F-actin filaments were stained with rhodamine-
phalloidin. Contractile-arrest resulted in disorganization and loss of F-actin filaments (Figure 
1a, Panel A and B), which was associated with redistribution of RhoA to peri-nuclear regions 
(data not shown) and a decrease in total RhoA expression (Figure 1b).  
 
Figure 1a. Effects of contractile arrest (a) and contractile activity (b) on actin-sarcomere organization in NVCM as 
determined by immunohistochemistry of F-actin. Contractile arrest resulted in an almost complete loss of actin-
sarcomere structure compared to contractile activity.  
 
 
 
 
Figure 1b. Western blot analyzes of total RhoA expression. Total protein was isolated from three different 
cultures of contraction-arrested NVCM (first three lanes) and from three different cultures of spontaneously 
contracting NVCM (last three lanes). Five µg of total protein was loaded in each lane, as confirmed by ponceau 
staining (not shown). 
F-actin staining
Contraction-arrested NVCM Spontaneously contracting NVCM
A B
contracting NVCMcontraction-arrested NVCM
Total RhoA
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4.4.2. RhoA-ROCK signaling in SERCA2a and ANF transcription regulation 
To investigate the role of RhoA-ROCK signaling in SERCA2a and ANF promoter 
regulation, contracting NVCM were transiently transfected with Luciferase-reporter plasmids 
driven by either the SERCA2a promoter (pS2 (6.6)) or by the ANF promoter (pANF (638)). 
Twenty-four hours after transfection, ROCK was inhibited by addition of the selective blocker 
Y-27632 (10 µmol/l) and cells were harvested 24 hours later. Y-27632-treatment did not 
affect contractile activity. Addition of the blocker resulted in a stimulation of SERCA2a 
promoter activity (+80 %) and repression of ANF promoter activity (-41 %) (Figure 2).  
 
Figure 2. Panel A: Effects of ROCK inhibition by Y-27632 (10 µmol/l) on SERCA2a promoter activity in NVCM. 
The pS2 (6.6)-Luc reporter plasmid was co-transfected with the CMV-pRL normalization plasmid. Y-27632 was 
added 24 hours after transfection and cells were analyzed 24 hours later. Y-27632 did not affect contractile 
activity. Data are presented as means ± SEM of six independent experiments. CTR: control. * p < 0.001 vs. CTR. 
Panel B: Effects of ROCK inhibition by Y-27632 (10 µmol/l) on ANF promoter activity in NVCM. The pANF (638)-
Luc reporter plasmid was co-transfected with the CMV-pRL normalization plasmid. Y-27632 was added 24 hours 
after transfection and cells were analyzed 24 hours later. Data are presented as means ± SEM of six independent 
experiments. CTR:control. * p < 0.001 vs. CTR. 
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4.4.3. Contractile-arrest and SRF expression 
Spontaneously contracting NVCM, spontaneously contracting NVCM treated with the 
ROCK inhibitor Y-27632 and contraction-arrested NVCM were transiently transfected with 
Luciferase-reporter plasmids driven by pSRE to detect SRF activity. Forty-eight hours after 
transfection, pSRE activity was lower in spontaneously contracting NVCM treated with the 
ROCK inhibitor Y-27632 (-25 %) and in contraction-arrested NVCM (-75 %), compared to 
untreated, contracting NVCM (Figure 3a). This indicates ROCK as well as contraction to be 
involved in SRF activation.  
  
 
 
 
 
 
 
 
Figure 3a.  Effects of contractile-arrest and ROCK inhibition on SRE-Luciferase activities. NVCM were transiently 
transfected with an SRE-reporter plasmid (pSRE) to detect SRF activities and with the CMV-pRL normalization 
plasmid. Y-27632 or BDM was added 24 hours after transfection and cells were analyzed 24 hours later. As a 
positive control for pSRE responsiveness, the SRF expression plasmid was also co-transfected. Data are 
presented as means ± SEM of at least five independent experiments. CTR: control. † p < 0.05 vs. CTR, ‡ p < 
0.001 vs. CTR, ♠ p < 0.001 vs. Y27632 (10 µmol/l). 
 
The expression of SRF-splice variants that could account for the reduced pSRE 
activity was tested by PCR analyzes, as described in the Material and Methods section. 
Equal levels of full length SRF transcript were identified in the spontaneously contracting and 
the BDM-treated NVCM with no detectable levels of splice variants (data not shown). 
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Next, SRF expression and localization were further analyzed by SRF 
immunohistochemistry. Nuclear SRF was lower in spontaneously contracting NVCM treated 
with the ROCK inhibitor Y-27632 (-11 %) and in contraction-arrested NVCM (-39 %), 
compared to untreated and contracting NVCM. Furthermore, treatment with Y-27632 had no 
additional effects in contraction-arrested NVCM (Figure 3b, c). Hence, both pSRE-activity 
and SRF immunohistochemistry imply that RhoA-ROCK signaling mediates contraction-
dependent activation of SRF. The relatively large difference in the observed SRF activities 
between Y27632-treated and BDM-treated NVCM most likely results from contraction-
dependent pathways that still can interfere in SRF regulation in the contracting Y27632-
treated cells, whereas in the BDM-arrested cells contractions were completely repressed, 
resulting in less SRF expression.   
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Figure 3b: Immunohistochemistry of 
nuclear SRF in spontaneously contracting 
NVCM, Y-27632 (10 µmol/l)-treated 
NVCM, BDM (7.5 mmol/l)-treated NVCM 
and BDM (7.5 mmol/l) + Y27632 (10 
µmol/l)- treated NVCM.  
Figure 3C: Quantification of nuclear SRF. 
The sum intensities of at least 30 cells 
from three independent experiments are 
shown. Data are presented as means ± 
SEM. CTR: control. † p < 0.001 vs. CTR; 
‡ p < 0.05 vs. CTR; ♠ p< 0.001 vs. 
Y27632. 
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4.4.4. SRF in SERCA2a and ANF transcription regulation 
 To analyze the transcriptional regulation of the SERCA2a and ANF promoter by SRF 
in the absence of cardiac-specific factors, transfection experiments were performed in COS7 
kidney cells, cultured under serum-free conditions. Using the pSRE reporter as an indicator 
of SRF activity an optimal (+ 80 %) stimulation of pSRE activity was obtained in COS7 kidney 
cells when pSRF was transfected at an input of 100 pg plasmid/10 cm2 (Figure 4a).  As 
previously reported by others 24-26, higher concentrations of exogenous SRF could not be 
used because of aspecific effects on transcription regulation. Transfection of pSRF did not 
alter ANF or SERCA2a promoter activity (Figure 4 b, c). Transfection of pMyocardin (100 
pg/10 cm2) in the absence of pSRF also failed to alter ANF or SERCA2a promoter activity 
(Figure 4b, c). Co-transfection of pSRF with pMyocardin resulted in a 620 % increase in ANF 
promoter activity (Figure 4b), but left SERCA2a promoter activity unaffected (Figure 4c.) 
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Figure 4. Panel A: Stimulation of SRE-Luc activity by 
exogenous SRF. COS7 kidney cells, cultured under serum-
free conditions, were transfected with various concentrations 
of the SRF-expression plasmid in order to detect the optimal 
SRF concentration. Maximal stimulation of SRE-activity was 
achieved after co-transfection of 100 pg SRF/10 cm2. Above 
this concentration aspecific regulation of the CMV-pRL 
normalization plasmid was observed. 
Panel B: COS7 kidney cells were cultured under serum-free 
conditions and were transiently transfected with the pANF 
(638)-Luc reporter. Luciferase activities were normalized to 
Renilla activities. ANF promoter activities were analyzed 
without co-transfection of transcription factors, in the 
presence of SRF, myocardin or both. Data are presented as 
means ± SEM of six independent experiments. CTR: 
control. † p<0.001 vs. CTR; ‡ p<0.01 vs. SRF; * p<0.01 vs. 
myocardin. 
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4.4.5. SRF and serum in SERCA2a transcription regulation 
Since co-transfection of pSRF with pMyocardin failed to alter SERCA2a promoter 
activity, co-factor-dependent control of SERCA2a promoter activity by SRF was further 
investigated by culturing COS7 kidney cells in serum-containing medium to explore the 
presence of such a co-factor in serum.  Under these conditions, pSRF lowered SERCA2a 
promoter activity by 23% (Figure 4d).  
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Panel C: COS7 kidney cells were cultured under serum-
free conditions and were transiently transfected with the 
pS2 (6.6)-Luc reporter plasmid. Luciferase activities were 
normalized to Renilla activities. SERCA2a promoter 
activities were analyzed without co-transfection of 
transcription factors, in the presence of SRF, myocardin 
or both. Data are presented as means ± SEM of six 
independent experiments. CTR: control. 
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Panel D: COS7 kidney cells were used to assess 
pS2-Luc promoter activity in serum-containing 
medium in the presence or absence of pSRF. 
Serum was added 24h after transfection. Data are 
presented as means ± SEM of six independent 
experiments. CTR: control. ** p<0.05 vs. serum 
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4.5. Discussion 
Development of maladaptive myocardial hypertrophy as a result of hemodynamic 
overload is associated with upregulation of ANF mRNA expression and downregulation of 
SERCA2a mRNA expression 1. Maladaptive myocardial hypertrophy and unfavourable LV 
remodeling can result from enhanced RhoA signaling 13;14,27-29,  which is associated with 
altered myofibrillar organization 30,31. In a variety of experiments using pro-hypertrophic 
stimuli such as lysophosphatidic acid 32, phenylephrine 9 and mechanical stress 33, enhanced 
RhoA signaling has been demonstrated to directly result in upregulation of ANF mRNA 
expression.  
 Although the role of RhoA signaling in the regulation of ANF mRNA expression and 
transcription is well established 9,34-36, its role in SERCA2a promoter regulation remains to be 
investigated. In contraction-arrested neonatal ventricular cardiomyocytes (NVCM), with 
unaffected calcium transients,  SERCA2a mRNA expression was recently demonstrated to 
depend on a synergistic upregulation of SERCA2a promoter activity by NFATc4 and MEF2c, 
the downstream transcription factors of the calcium-dependent calcineurin and CAMK-II 
pathways, respectively 5. In this model, contractile activity suppressed SERCA2a mRNA 
expression by a mechanism that was apparently independent of the calcineurin signaling 
pathway since nuclear translocation of NFAT was similar in spontaneously contracting and 
arrested NVCM. The current study identifies RhoA signaling to be involved in the 
upregulation of ANF promoter and the downregulation of SERCA2a promoter activity as a 
result of contractile activity. The RhoA signaling-induced upregulation of ANF promoter 
activity is mediated by SRF, which, based on the COS7 data, requires the presence of 
myocardin. The RhoA signaling-induced downregulation of SERCA2a promoter activity also 
is mediated by SRF but requires the presence of a co-factor different from myocardin. This 
co-factor remains to be identified.  
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4.5.1. Contractile arrest, RhoA-ROCK signaling and transcription regulation 
 Following three days of contractile arrest, the cultured NVCM of the present study had 
a disorganized cytoskeleton, as evident from the rhodamin-phalloidin staining of the F-actin 
filaments (Figure 1a panel A and B). Since RhoA signaling is closely linked to F-actin 
organization, the previously observed contractile arrest-induced increase in SERCA2a 
mRNA expression could have resulted from suppression of RhoA signaling because of 
cytoskeletal disorganization. Following three days of contractile arrest, total RhoA expression 
was indeed impaired (Figure 1b) and redistributed to peri-nuclear regions (data not shown). 
Furthermore, treatment of cells with Y-27632 for 24 h, which selectively blocks the activation 
of ROCK, resulted in upregulation of SERCA2a promoter activity and downregulation of ANF 
promoter activity (Figure 2). Since Y-27632 did not affect F-actin organization, its effects on 
SERCA2a and ANF must have resulted from blocked activation of ROCK and not from 
reduced contractile activity. This ability of ROCK to induce opposite changes in ANF and 
SERCA2a gene expression confirms an earlier report which showed decreased Rho kinase 
activity to blunt pathological myocardial hypertrophy in a model of hypertension-induced 
heart failure 13. However, since the present study rests on an experimental approach which 
reduces contractile activity by inducing contractile arrest, extrapolation of the current results 
to an experimental setting where contractile activity is augmented by raising mechanical load 
warrants caution. 
 
 
4.5.2. SRF splice variants and transcription regulation 
 
 Previous studies have described serum response factor (SRF) as a downstream 
transcription factor of the RhoA-ROCK signaling pathway 15,16.  In the in vivo setting of 
mechanical overload, there is evidence that hemodynamic stress controls gene expression 
not through SRF itself, but through generation of SRF splice variants. As described by Davis 
18 and Kemp 37, SRF splice variants can function as dominant negative factors in transcription 
regulation. These splice variants have also been observed in failing human myocardium. 
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Because expression of these SRF splice variants is observed under conditions of increased 
mechanical load, it was proposed that contractile arrest of spontaneously contracting NVCM 
may prevent the generation of SRF splice variants in this model. However, PCR analyses 
failed to reveal SRF splice variants in both the contraction-arrested and spontaneously 
contracting NVCM. This suggests in vitro contractile load not to be sufficiently high to 
generate these splice variants, or other factors to be involved in their generation in vivo 17. 
 
4.5.3. SRF and transcription regulation 
 
 The present study confirms by immunohistochemistry the nuclear translocation of 
SRF as a result of RhoA-ROCK signaling and shows contractile activity to activate the RhoA-
ROCK-SRF signaling cascade. The observed difference of SRF activities between Y-27632-
treated cells and BDM-treated cells may result from contraction-dependent pathways other 
than the RhoA-ROCK pathway, that remain active following Y-27632-treatment and can 
activate SRF, in contrast to the BDM-treated cells that have no contractile activity left. To 
monitor direct effects of the muscle specific factors SRF and myocardin in ANF and 
SERCA2a promoter regulation in the absence of other cardiac-specific factors, SRF co-
transfection experiments were performed in COS7 kidney cells. In contrast to the 
experiments using the ROCK blocker Y-27632, which indicated regulation by RhoA-ROCK 
signaling of ANF and SERCA2a transcription, co-transfection of SRF did not result in altered 
promoter activity of either gene. This finding also contrasts with the altered ANF and 
SERCA2a gene expression observed in transgenic mice overexpressing SRF and with an 
earlier study that observed enhanced ANF promoter activity following co-transfection of SRF 
23. The presence of serum in the culture medium used in the latter study may explain the 
observed SRF-dependent transcription regulation. SRF-dependent transcription regulation of 
SERCA2a was also observed in the present study when COS7 cells were maintained in 
serum-containing medium. In serum-containing medium, transfection of SRF resulted in a 23 
% downregulation of SERCA2a promoter activity. This implies the involvement of a serum-
dependent co-factor required for the transcriptional repression of SERCA2a transcription by 
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SRF. Serum-induced nuclear translocation of the SRF co-activator MAL has indeed been 
shown for NIH3T3 cells 10. 
 Myocardin is closely related to MAL and increased expression of myocardin mRNA 
has been previously observed in failing human myocardium 21. However, our data do not 
support a role for myocardin in the SRF-dependent repression of SERCA2a expression, 
since co-transfection of myocardin and SRF in COS7 cells under serum-free conditions did 
not affect SERCA2a promoter activity. In contrast, ANF promoter activity was strongly 
stimulated by this combination of factors. The present study therefore indicates that the 
control by SRF of ANF upregulation and SERCA2a downregulation is dependent on different 
co-factors, namely myocardin for ANF and an unidentified co-factor for SERCA2a (Figure 5). 
 
4.5.4. Conclusions 
As summarized in Figure 5, the current study provides evidence indicating that contractile 
activity exerts opposite effects on the ANF and the SERCA2a promoters through the RhoA-
ROCK-SRF signaling cascade. Contractile activity organizes the actin cytoskeleton, which 
promotes RhoA-ROCK signaling and leads to enhanced SRF activity. The latter upregulates 
ANF promoter activity in the presence of myocardin and down-regulates SERCA2a promoter 
activity in the presence of an unidentified factor. 
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Figure 5. RhoA-ROCK-SRF signaling in the control of ANF and SERCA2a gene transcription. 
Contractile-arrest disorganizes the F-actin cytoskeleton and decreases total RhoA protein expression. 
Contractile activity exerts opposite effects on ANF and SERCA2a promoter regulation via organization 
of the F-actin cytoskeleton and via a concomitant activation of RhoA-ROCK signaling, which can be 
inhibited by Y-27632. SRF is involved in this RhoA-ROCK-dependent regulation. SRF controls 
enhancement of ANF transcription via an association with the cofactor myocardin and SRF controls 
repression of SERCA2a transcription via an association with an unidentified cofactor.  
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5.1. Abstract 
The mechanism responsible for repressed SERCA2a expression observed during 
pathological cardiac hypertrophy is suggested to be transcriptional. Previous in vivo studies 
using transfection of myocardium by direct injection of SERCA2a promoter-Luciferase 
plasmids, have demonstrated in a model of left ventricular (LV) pressure overload that the 
proximal 1.8 kb rabbit SERCA2a promoter fragment contains load-responsive elements.  
However, the high homology observed between the mouse and rat SERCA2a promoters 
indicated that the physiologically relevant length of the murine SERCA2a promoter may 
extend to at least 4.1 kb. In the present study we tested whether the technique of in vivo 
DNA transfer can be used to analyze transcriptional activity of SERCA2a promoter fragments 
of up to 6.6 kb in length.  In addition, the technique was optimized to also include transfection 
of the RV. This allows the use of either RV or LV pressure-overload models, with the non-
hypertrophic ventricle serving as a control for the overloaded ventricle. Hearts of 36 control 
rats were exposed via a right-sided thoracotomy and Firefly Luciferase (Luc) reporter 
plasmids driven by 0.5, 3.2 or 6.6 kb of the SERCA2a promoter (pS2-0.5 Luc, -3.2 Luc and -
6.6 Luc, respectively) were injected into the free wall of both the LV and RV. Five days later 
Luc expression was determined in ventricular homogenates and normalized using the activity 
of a co-transfected Renilla Luciferase reporter plasmid driven by the CMV promoter (CMV-
pRL). The success rate of the in vivo transfections was 56 % for LV and 81 % for RV 
injections. In 45 % of the experiments, both RV and LV of the same heart were successfully 
transfected. Normalized pS2-Luc activity increased with increasing length of the S2-
promoter. There were no significant differences in transcriptional activity of the pS2-Luc 
constructs between LV and RV. Finally, the method was tested for use with the model of 
monocrotaline (MCT) induced pulmonary hypertension and subsequent RV hypertrophy and 
failure. Hearts of MCT-treated rats (n=6, 80mg MCT/kg) were transfected with pS2-6.6 Luc 
and CMV-pRL at day 16 following MCT administration and analyzed at day 21. The success 
rates of RV and LV transfections and levels of pS2-6.6 Luc activity were similar to those 
found for control rats. In conclusion, the experimental protocol described here allows 
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promoter analysis in both LV and RV in vivo. Furthermore, the presented data show for the 
first time that the SERCA2a promoter of 6.6 kb in length directs strong transcriptional activity 
in vivo, which warrants further analysis of the regulatory properties of the far-upstream part of 
this promoter.   
Chapter 5 
 
 
 
106
 5.2. Introduction  
 
 In vivo hemodynamic cardiac overload is associated with altered mRNA expression 
profiles 1,2,  including a down-regulation of expression of the sarco-endoplasmic reticulum 
calcium ATPase 2a (SERCA2a) gene 3. Reduced expression of this calcium transporter 
further contributes to the development of pathological cardiac hypertrophy. Previous in vitro 
studies using a model of isolated spontaneously contracting neonatal ventricular 
cardiomyocytes (NVCM) have demonstrated that the calcium-dependent signaling pathways 
calcineurin/nuclear factor of activated T-lymphocytes c4 (NFATc4) and calmodulin kinase II 
(CAMK-II)/ myocyte enhancer factor 2c (MEF2c) can stimulate SERCA2a mRNA expression 
and promoter activity. This stimulation was abrogated by contractile activity 4. Candidate 
contractile activity-induced mediators involved in the repression of SERCA2a transcription 
appeared to be the RhoA-ROCK-SRF cascade and enhanced GSK3β activity (Chapters 3 
and 4).  
Several studies have described repressive effects of enhanced left ventricular (LV) 
pressure overload on SERCA2a promoter activity in vivo 5. These studies used either 
transcriptional run-on assays of nuclei isolated from overloaded rat LV, or in vivo direct gene 
transfer of rabbit SERCA2a promoter constructs in overloaded rat LV 6-8. The latter studies 
have suggested that important load-responsive elements, located within the first 1.8 kb of the 
rabbit SERCA2a promoter, contribute to the down-regulation of SERCA2a expression. A 
limitation of these studies, however, is the use of the rabbit SERCA2a promoter in a rat 
model of LV overload. Homology searches revealed that the rabbit SERCA2a promoter is 
only in part similar to that of the rat up to 1.5 kb, whereas multiple conserved sequences are 
present in the rat and mouse SERCA2a promoter up to 4.1 kb 4. This suggests that the 
upstream parts of the murine SERCA2a promoters may play a role in the control of 
SERCA2a gene expression. It further implies that previous in vitro studies using shorter 
deletion variants of the rat SERCA2a promoter may have missed important regulatory 
mechanisms of these more up-stream located sequences 9-11.  
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The technique of direct gene transfer in myocardium provides a relatively 
straightforward analysis of the effect of promoter deletions on transcriptional activity in vivo, 
but only short promoter fragments (< 3.2 kb) have thus far been analyzed. In the present 
study we therefore tested whether the technique can be used to analyze activity of SERCA2a 
promoter fragments of up to 6.6 kb in length. Transfection of cells in situ by injection of 
plasmid DNA was first shown for skeletal muscle 12 and later also for rat and mouse 
myocardium 6,7,13,14, see also a recent review of this technique by Dean 15. The mechanism of 
plasmid uptake is unknown, but appears to be an exclusive property of muscle cells 13. 
Consequently, transfection of myocardium is restricted to cardiomyocytes which simplifies 
the interpretation of data. However, the efficiency of transfection is low and highly variable, 
requiring normalization by co-transfection of a reporter plasmid driven by a non-regulated 
promoter. Furthermore, because of the difficulty of injecting the free wall of the thin RV, only 
transfections of the LV have thus far been reported. In this study we therefore also aimed to 
transfect the RV. This would allow the use of either RV or LV pressure-overload models, with 
the non-hypertrophic ventricle serving as a control for the hypertrophic ventricle. In particular, 
we tested whether bi-ventricular transfection is possible in the rat model of monocrotaline 
(MCT)-induced pulmonary hypertension and RV hypertrophy. This model is used for the 
analysis of gene expression alterations following RV pressure overload.  
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5.3. Material and Methods 
5.3.1. Animals 
 All animals were treated according to the national guidelines and with the permission 
of the Institutional Animal Care and Use Committee (IACUC) of the VU University Medical 
Center, the Netherlands. 
 
 
5.3.2. Preparation of plasmids 
 Deletions variants of the SERCA2a promoter with 5’- ends at -6588 bp, -3263 bp and 
-550 bp and with 3’-ends at +550 bp were excised with HincII-NcoI, HindIII-NcoI and EcoRI-
NcoI, respectively and cloned into unique sites of the promoterless pGL3-Luciferase plasmid 
(Promega, Madison, USA). The CMV-pRL plasmid was used for normalization (Promega, 
Madison, USA). Plasmid preparations were purified using Qiagen Maxi columns (Qiagen, 
Dusseldorf, Germany) and dissolved in water.  
 
5.3.3. In vivo experimental procedures 
Male Wistar rats (n=44; mean body weight 191 ± 12.7 g; Harlan CBP, Horst, The 
Netherlands) were randomly assigned to a control (CON, n=37) or MCT-treated group (MCT, 
n=7). Animals were conventionally housed and received food and water ad libitum. Briefly, 
after one week of acclimatization, animals received either a single subcutaneous injection of 
MCT (80 mg/kg), or saline (0.9 % NaCl). Animals were weighed twice a week, and two 
weeks after MCT or saline injection, animals were weighed daily. Direct gene transfer of DNA 
plasmids was performed 16 days after the MCT or saline injection.  
Three weeks after MCT or saline injection, animals were sacrificed by excision of the 
heart under sevoflurane anesthesia. All MCT-treated animals showed signs of congestive 
heart failure (CHF) such as weight loss, pleural effusion, liver cirrhosis and ascites.  
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5.3.4. Direct gene transfer in the adult rat myocardium 
Rats were anesthetized with a mixture of N2O (0.2 l/min), O2 (0.2 l/min) and 
sevoflurane (2-3 %). Hearts were exposed through a right lateral thoracotomy. Per ventricle, 
three injections were performed with a total volume of 100 µl of normal saline containing a 
cocktail of 10 µg of either pS2 (0.5)-Luc, pS2 (3.2)-Luc or pS2 (6.6)-Luc and 5 µg of pCMV-
pRL normalization plasmid. The β-galactosidase expression plasmid pcDNA 3.1 was injected 
in two seperate experiments to assess the transfection of RV cardiomyocytes in a control 
and an MCT-treated rat. Frozen tissue sections (5 µm) were stained for β-galactosidase 
expression with X-Gal.  'Insulin' syringes (Beckton, Dickinson, Le Pont de Clair, France) with 
29 gauge needle and zero dead volume were used for the injections. For injection of the RV, 
needles were bent at the tip to a 90 degree angle. This allows the approximately 3 mm long 
horizontal tip to be inserted under a very shallow angle into the free wall of the RV. Following 
injection, the thorax was closed in layers and rats were allowed to recover with an 
intraperitoneal injection of temgesic. Animals were sacrificed five days after the direct gene 
transfer.  
 
5.3.5. Tissue homogenization and Luciferase assay 
 Rats were anesthetized with sevoflurane (3.5 %). Hearts were excised and briefly 
rinsed in normal saline solution (0.9 % NaCl). LV, RV and septum were divided, weighed, 
snap frozen in liquid nitrogen and stored at -80°C until further use. Tissue samples were 
homogenized in 200 µl / 100 mg tissue of the Luciferase lysis buffer (Promega, Madison, 
USA) and centrifuged for 15 minutes at 12,000 x g at 4°C. Ten µl of the supernatant of the 
myocardial homogenates was used in the combined Firefly and Renilla Luciferase assay, 
according to the manufactures protocol. Light emissions were determined using a 
luminometer (Lumat 9507, Berthold, Bad Wildbad, Germany). Luciferase activities were 
normalized to Renilla activities.  
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5.3.6. SERCA2a -protein determination    
 Immunodetection was performed by a modification of the method described earlier 16. 
Total protein concentrations in myocardial homogenates in Luciferase lysis buffer were 
determined using the BCA protein assay kit (Pierce, Rockford, USA). Samples were diluted 
in PBS/1 % SDS, incubated at 37°C for 10 minutes and 1 µl containing 0.3 µg of protein was 
spotted on nitrocellulose membranes (0.45 µm, Biorad). Blots were blocked in PBS/3 % 
BSA/0.05 % Tween 20 (Sigma, Zwijndrecht, The Netherlands) for two hours and incubated 
for one hour with the polyclonal rabbit SERCA2a antibody (generous gift from Dr. F. 
Wuytack) 1:8000 diluted in blocking buffer. The secondary antibody (Jackson, 
Cambridgeshire, UK) was labeled with Na125I (Amersham, Roosendaal, The Netherlands), 
using Iodo-gen pre-coated tubes (Pierce, Rockford, USA). The binding of secondary antibody 
was detected by exposure to Phosphor imager screens and analyzed with ImageQuant 
software (Molecular Dynamics, Staubenhardt, Germany).  
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5.4. Results 
5.4.1. Bi-ventricular plasmid DNA transfer  
 The experimental set-up for the in vivo injection of plasmid DNA in myocardium is 
shown in Figure 1. Panel A shows the intubated anesthetized rat, subjected to controlled 
ventilation. Injection of the RV with the tip of the needle bent to a 90 degree angle is depicted 
in panel B. Because of the right lateral thoracotomy, the RV is directly exposed and therefore 
relatively easy to inject, whereas the LV is less accessible. Injection of the LV was done with 
a slightly curved needle, inserted into the left side of the heart. Unlike the RV injections, it 
was not possible to see the position of the tip of the needle at the time of injection of  the LV. 
Panels C and D show representative images of tissue sections from the RV of  a control (C) 
and an MCT-treated rat (D), transfected with an expression plasmid for β-galactosidase. X-
Gal staining of the tissue sections reveals the transfected myocytes. In agreement with 
previous data, we did not find other cell types positive for β-galactosidase. Identical results 
were obtained for LV sections (not shown).  
 
Figure 1. Illustrations of in vivo direct 
SERCA2a-promoter plasmid transfer in the 
rat LV and RV at day 16 of the experimental 
protocol. Panel A: Intubated anesthetized rat, 
subjected to controlled ventilation. Panel B: 
Direct DNA-plasmid transfer in LV and RV, 
per ventricle a total volume of 100 µl of 
normal saline containing a cocktail of 10 µg of 
either the pS2 (0.5)-Luc, the pS2 (3.2)-Luc or 
pS2 (6.6)-Luc and 5 µg of pCMV-Renilla 
normalization plasmid was injected. Panel C: 
β-Galactosidase staining CON RV myocytes, 
indicating that the DNA transfer was 
successful and expression can be monitored 
5 days after DNA-transfer (see arrow). Panel 
D: β-galactosidase staining MCT RV 
myocytes. 
 
A B
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5.4.2. Measurement of SERCA2a promoter activity 
Figure 2 schematically depicts the 6.6 kb SERCA2a promoter and the areas of sequence 
homology between the rat, mouse, rabbit and human sequences. The pS2-Luc reporter 
plasmids driven by either 0.5 kb, 3.2 kb or the full length rat SERCA2a promoter were 
injected together with the CMV-pRL normalization plasmid in the myocardium of both 
ventricles of 36 CON rats. Five days after injection, rats were sacrificed and LV and RV 
homogenates were analyzed for Firefly and Renilla Luciferase activities.  
 
Figure 2.  Schematic representation of the homologies of SERCA2a promoter sequences among four 
different species (rat, mouse, rabbit and human). The numbers above the rat SERCA2a promoter 
represent the rough length of the SERCA2a promoter-Luciferase constructs (0.5; 3.2 and 6.6 kb). The 
dark-colored boxes represent highly homologous promoter regions compared to the rat SERCA2a 
promoter sequence. The mouse and rat SERCA2a sequences are highly homologous to 
approximately 4.1 kb. 
 
Sufficient Luciferase activities, i.e., more than 2-fold over background, were observed for 29 
(81 %) of the RV injections and 22 (56 %) of the LV injections. In 16 animals both ventricles 
were successfully injected. In the Luciferase analyzes 10 µl of homogenate, containing 3.3 
mg of tissue wet weight, were assayed and pS2-Luc activities ranged from 0.3x103 - 3.5x105 
SERCA2a promoter SERCA2a gene
6.6 4.1 3.2 
Rat 12q16
Mouse 5F
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Human chr
12q23-24.1
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RLU. The range of activity of the CMV-pRL normalization plasmid was similarly wide, i.e., 
6.0x103 - 2.5x106 RLU, reflecting the variability in transfection efficiency. Figure 3 
summarizes the normalized pS2-Luc activities of the three promoter constructs in the RV and 
LV, showing no significant difference in activity of a given construct between both ventricles. 
Activity of pS2 (3.2)-Luc was approximately 2-fold higher than that of pS2 (0.5)-Luc  
(2p<0.007). Activity of pS2 (6.6)-Luc was again 50 % higher than that of pS2 (3.2)-Luc, but 
this was not statistically significant due to the relatively large variation in activities of this 
construct. The difference between the highest and lowest normalized pS2-Luc 6.6 activities 
was 10 fold, whereas this was 5 fold for pS2 (3.2)-Luc and 2 fold for pS2 (0.5)-Luc. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LV RV
0.00
0.01
0.02
0.03
 p
S2
 (0
.5
) L
uc
/R
en
 r
at
io
 r
es
po
ns
e
in
 a
t l
ea
st
 o
ne
 v
en
tic
le
(A
U
)
C 
B A 
Figure 3. SERCA2a promoter-Luciferase activities 
detected in LV and RV of CON rats. Thirty-six rats were 
injected with either the pS2 (0.5) [A], (3.2) [B], or (6.6) 
[C] promoter fragment. RV Luc and Ren activities were 
detected in 81 % [29/36], whereas LV Luc and Ren 
activities were detected in 56 % [21/36]. Luc/Ren ratio’s 
are shown in absolute units (AU). Data are presented 
as mean ± SEM. 
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5.4.4. Feasibility of the technique in a model of RV hypertrophy 
We next tested whether the technique of bi-ventricular plasmid transfer can be 
applied to the monocrotaline (MCT) model of RV hypertrophy. The MCT model of RV 
pressure overload is used in our laboratory to investigate the process of ventricular 
hypertrophy and in particular the mechanism underlying the downregulation of SERCA2a 
expression in heart failure. A single dose of MCT damages the vascular endothelium leading 
to increasing pulmonary resistance and subsequent RV hypertrophy 17. A low dose of MCT 
(30 mg/kg) induces compensatory hypertrophy 18, whereas a high dose (80 mg/kg) induces 
the development of RV failure over a period of 28 days19-21. Because the ultimate aim is to 
analyze the down regulation of SERCA2a promoter activity leading up to heart failure, we 
tested the feasibility of the technique at three weeks following administration of 80 mg/kg 
MCT. SERCA2a expression is already reduced at this time.  
In this pilot series, six MCT-treated animals were injected with a mix of pS2 (6.6)-Luc  
and the CMV-pRL normalization plasmid and one with pcDNA 3.1 to confirm the transfection 
of cardiomyocytes (see Figure 1). The growth characteristics of the MCT-treated rats are 
illustrated in Figure 4, together with those of the control (CON) group. The slight drop in body 
weight after 17 days in both the CON and the MCT group is due to the open-chest surgery 
and the plasmid DNA transfer. MCT-treated rats start losing weight from day 18. In addition 
to the loss in body weight after day 18, MCT-treated animals showed secondary effects of 
right sided failure such as pleural effusion. Table 1 summarizes the organ and body weights 
of the animals that were sacrificed 21 days after injection of saline or MCT. 
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Figure 4. Growth characteristics of CON rats and MCT-treated rats. Total body weight (gram) was 
monitored during the experimental protocol after the saline or MCT injection at day 0. A decreased 
gain in body weight was observed in all MCT-treated animals up to 18 days after the injection, 
compared to control animals. The drop in body weight observed in all animals at 16 days is most likely 
due to the open-chest surgery together with the direct transfer of plasmid DNA in the ventricles. At day 
18 MCT-treated animals started losing body weight, which is a characteristic of heart failure. 
    
  body weight (g) RV (mg) LV (mg) RV/LV+sept ratio total heart (g) lung (g) 
Control 293±6     158±6  354±13      0,21±0,01 926±23  1,33±0,03 
MCT  245±6 †     285±10 ‡  296±13 ‡      0,41±0,02 ‡ 985±26  2,2±0,07 ‡ 
 
 
Table 1.  Body and tissue weights of Control and MCT-treated rats. Data are presented as means  ± 
SEM of at least 12 rats. † p<0.05 vs. Control; ‡ p<0.01 vs. Control. 
 
As evident from Figure 5, SERCA2a protein expression was decreased by 25 % in 
the RV following right-sided pressure overload, as compared to both the LV of the same 
group and the RV of the CON group. In control hearts SERCA2a protein expression was 
equal in both ventricles.  
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In this pilot series all seven animals survived the procedure and of the six hearts injected with 
the Luciferase constructs, five RV's and four LV's were successfully transfected. The 
normalized pS2 (6.6)-Luc activities are presented in Figure 6, showing no difference between 
the RV and LV. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CO
N 
LV
MC
T L
V
CO
N 
RV
MC
T R
V 
0
25
50
75
100
125
SE
R
C
A
2a
 p
ro
te
in
 e
xp
re
ss
io
n
pm
ol
/m
g 
ei
w
it
‡† Figure 5. Quantification of total SERCA2a 
protein expression in LV and RV 
homogenates of CON (open bars) and 
MCT-treated rats (filled bars) at day 21. RV 
MCT total SERCA2a protein is significantly 
decreased compared to LV MCT SERCA2a 
protein expression and compared to RV 
CON, whereas SERCA2a protein was 
similarly expression in RV and LV in CON 
rats. Data are presented as means  
± SEM of at least 6 ventricles. CON: control. 
‡ p<0.05 vs. RV CON. † p<0.05 vs. LV MCT 
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Figure 6. SERCA2a promoter (pS2 (6.6))-
Luciferase activity detected in LV and RV 
in MCT-treated rats. Six rats were injected 
with the pS2 (6.6) promoter fragment. 
Luc/Ren ratio’s are shown in absolute 
units (AU). Data are presented as mean ± 
SEM. 
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5.5. Discussion 
Our previous in vitro studies (Chapters 3 and 4) have suggested that important 
regulatory elements may be present in relatively far upstream regions of the rat SERCA2a 
promoter. This is further supported by the high degree of homology between the rat and 
mouse SERCA2a promoter sequence up to approximately 4.1 kb. Whether such conserved 
sequences may be involved in the critical downregulation of SERCA2a expression in 
pathological hypertrophy, may be tested by in vivo transfection of ventricular myocytes with 
SERCA2a promoter-reporter constructs. Using this technique of plasmid DNA transfer and 
subsequent reporter analysis 15 rabbit SERCA2a promoter fragments of 1.8 kb have been 
analyzed in a rat model of LV overload, indicating the presence of load-responsive elements 
6-8. Because it is our aim to analyze the full length rat SERCA2a promoter in a rat model of 
RV pressure overload, we tested in the present study 1: the possibility of transfecting both 
the LV and the RV, 2: the possibility of transfecting and analyzing SERCA2a promoter 
constructs comprising up to 6.6 kb of promoter sequence, 3: the feasibilty of this technique 
for use with the MCT model of RV hypertrophy and failure.  
 
5.5.1. Bi-ventricular plasmid DNA transfer in control and MCT-treated rats  
 The combination of a right-sided thoracotomy and injection using a 29 gauge needle 
bent at the tip, proved successful in transfecting the RV of both control and MCT-treated rats. 
The success rate of 80 % was not reached for the LV injections (60 %), which is in part due 
to the fact that the LV is less exposed. Cutting one rib and briefly lifting the heart from the 
thoracic cavity may be used to gain better access to the LV. However, it should be noted that 
success rates are typically not higher than 75 %, even with injection of an exposed LV (K. 
Ojamaa, personal communication).  
Confirming previous studies 13,22 we found only cardiomyocytes positive for β-
galactosidase activity following transfection of pcDNA 3.1, with positive cells primarily located 
along the needle track. Although we did not score the number of positive cells, we estimate 
that fewer than 200 cells were transfected per injection spot, in line with earlier reports 13,22.   
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Analysis of the MCT model using the current protocol appears to pose no problems. The 
response of MCT-treated animals to the surgery and plasmid transfer 16 days after MCT 
administration was identical to that of controls. With the exception of a brief period of weight 
loss directly following surgery, which was observed in all animals, growth curves and general 
parameters of hypertrophy in this MCT group at the time of sacrifice (day 21) were 
furthermore the same as reported earlier 19.  
 
5.5.2. Analysis of SERCA2a promoter sequences up to 6.6 kb in length 
 The efficiency of transfection is highly variable with specific Luciferase activities (Luc 
or Ren) varying by a factor of 500-1000. This is in agreement with data obtained by Ascadi et 
al. 13, underscoring the need for co-transfection of a normalization plasmid 14,22. Based on 
numerous in vitro experiments it is generally accepted that a transfected cell takes up 
multiple copies of the different plasmids present in a transfection mix, allowing normalization. 
Indeed, our normalized data show only several fold variation in the specific activities of either 
pS2 (0.5)-Luc or pS2 (3.2)-Luc. The relative standard deviation of the normalized Luc 
activities for both constructs in the control group was approximately 50 % (Figure 3), which is 
similar to data obtained by Ojamaa et al. 14 with the in vivo analysis of an 1145 bp βMHC 
promoter-Luciferase construct in rat LV.  
However, the variability of normalized pS2 (6.6)-Luc activities was substantially 
higher, i.e., 10 fold, both in the control and the MCT series. This resulted in relative standard 
deviations of approximately 150 %, seriously limiting the sensitivity of the technique. This 
variability can not be ascribed to inter-animal, or inter-assay variation, since widely different 
values were also observed in those experiments where RV and LV activities of the same 
animal were determined (data not shown). Several reasons may be suggested for the greater 
variability in expression of the 6.6 kb promoter-Luciferase construct: 1. Reduced stability of 
the relatively large pS2 (6.6)-Luc plasmid. Although typical plasmid DNA (~5 kb) is stable in 
in vivo transfected cardiomyocytes for at least 60 days 13,15 it can not be excluded that the 
11.4 kb pS2 (6.6)-Luc  plasmid is susceptible to degradation; 2. The long promoter fragment 
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may be more susceptible to progressive inactivation by DNA methylation 15; 3. Differences in 
SERCA2a expression have been reported between endo- and epicardial myocytes 23 and 
because only cells around the injection spot are transfected,  it can not be excluded that part 
of the variation stems from injections in different regions of the ventricle wall. However, the 
difference in SERCA2a expression between different regions is small compared to the 
observed variation in promoter activity.  
Whether the variation is due to regulation of the 6.6 kb promoter, or to degradation, 
may be tested by determining the actual plasmid content of the tissue homogenates by 
quantitative PCR. This will allow expression of the Luciferase activities of the various 
constructs relative to their respective plasmid levels. The analysis should also include a pS2 
(4.1)-Luc construct, since it may contain the essential regulatory sequences. This construct 
may not yet suffer from the effects of plasmid size and would allow the analysis of load-
dependent regulation of SERCA2a transcription in the context of the intact promoter. On the 
other hand, if this size of the plasmid is already a limiting factor, then sections of the 
upstream regions may be analyzed after inserting them upstream of a truncated promoter 
fragment, giving a total length of less than 3.2 kb. Alternatively, the CMV-pRL plasmid may 
be used for the SERCA2a promoter-reporter constructs, as this plasmid is 1.5 kb smaller 
than the pGL3 plasmid currently used for the pS2-Luc constructs. 
 
5.5.3. In vivo activity of transfected SERCA2a promoter fragments 
 Our earlier analyzes of the pS2-Luc constructs in transfection studies using cultured 
neonatal ventricular cardiomyocytes, showed a progressive reduction of transcriptional 
activity with increasing length of the promoter (Chapter 2). In contrast, our in vivo data 
indicate a significant, 2 fold higher activity of the 3.2 kb sequence, compared to the 0.5 kb 
sequence (Figure 3). Moreover, the average activity of the 6.6 kb promoter was 10 fold 
higher compared to the short sequence. This difference was not statistically significant, but 
as discussed above, the activity of pS2 (6.6)-Luc is most likely underestimated because of 
variable degradation or inactivation of the construct. This suggests the presence of 
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transcription factors unique to adult cardiomyocytes, that enhance SERCA2a transcription 
through interaction with promoter elements located between positions 0.5 and 3.2 kb, and 
possibly also between positions 3.2 and 6.6 kb.   
 
In conclusion, the present protocol allows the in vivo plasmid DNA transfer of both the 
RV and the LV and is compatible with the MCT-model of RV hypertrophy and failure. The 
advantage of bi-ventricular transfection is that it allows to make a distinction between 
ventricle-specific and systemic effects. Reproducible transfection and analysis of SERCA2a 
promoter-Luciferase constructs is feasible for plasmid constructs of up to 8 kb in length. The 
unexpectedly high transcription activity of the 6.6 kb SERCA2a promoter sequence warrants 
further analysis of the far upstream regions of this promoter. 
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6. Conclusions and general discussion 
This thesis characterizes the rat SERCA2a promoter in an in vitro model of isolated 
spontaneously contracting neonatal cardiomyocytes. In the preceding chapters the following 
issues have been addressed: 1.) The in vitro regulation of rat SERCA2a transcription and 
mRNA expression by load- and calcium-dependent signal transduction, 2.) Identification of 
load- and calcium-dependent regulatory factors involved in the regulation of SERCA2a 
transcription 3.) Description of in vivo gene transfer as a method to investigate in vivo 
regulation of rat SERCA2a promoter activity.  
ANF expression was included in the study as a marker for hypertropic signaling.  
 
6.1. Main findings (see Figure 1) 
6.1.1. In vitro results 
1. A balance between stimulatory calcium-dependent signal transduction and inhibitory       
contractile activity-dependent signal transduction sets in vitro SERCA2a and ANF mRNA 
expression. 
2. The activity of the 6.6 kb SERCA2a promoter is stimulated by a combination of the 
calcium-dependent transcription factors NFATc4 and MEF2c. 
3. Mechanical load-induced RhoA-ROCK-SRF signaling reciprocally regulates the activity of 
the 6.6 kb SERCA2a promoter and the 638 bp ANF promoter. The RhoA-dependent 
transcription factor SRF together with myocardin stimulates the ANF promoter, whereas SRF 
together with an as yet undetermined factor represses SERCA2a promoter activity. 
4. The pro-hypertrophic transcription factor GATA4 stimulates activity of the 6.6 kb SERCA2a 
promoter via a muscle-specific mechanism. 
5. Contractile arrest enhances nuclear accumulation of GATA4 and NFATc4, which is likely 
to be mediated by a decreased GSK3β activity. Pharmacological inhibition of GSK3β activity 
induces a stimulation of 6.6 kb SERCA2a promoter activity. 
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6.1.2. In vivo results 
Direct gene transfer of SERCA2a promoter-Luciferase constructs into the 
myocardium resulted in detecTable Luciferase activities in RV and LV within one heart of 
CON and MCT-treated rats. Furthermore, the 6.6 kb fragment of the SERCA2a promoter 
showed a Luciferase activity that was similar to that of the shorter fragments. These results 
show that this method allows in vivo analysis of (load-dependent) transcriptional regulation of 
SERCA2a promoter fragments up to 6.6 kb. 
 
 
Figure 1 
Overview of the regulation of the activity of the 6.6 kb SERCA2a promoter based on the in vitro results 
described in this thesis.  
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6.2. Methodological considerations 
6.2.1. Maintaining in vitro contractile activity of NVCM 
The use of regular contracting NVCM as a model, required careful optimization of 
several essential parameters. First, cultured NVCM exhibit regular and constant spontaneous 
contractions at a density of 7-8 x 104 cells/cm2.  Alterations in density affected cellular 
contraction rate. Secondly, direct cell-to-cell contact of isolated NVCM is essential to produce 
regular and constant contractions. Even at a density of 7-8 x 104 cells/cm2, direct cell-to-cell 
contact is only achieved in proximally four days after the isolation procedure provided these 
cells were cultured in serum-containing medium. After this time-period, serum-containing 
medium can be changed to serum-free medium and NVCM produce regular and constant 
spontaneous contractions during the experimental period of three days.  
 
6.2.2. Contractile arrest of NVCM following BDM-treatment 
BDM-treatment did not result in an immediate cessation of contractile activity, but 
irregular contractions remained visible and decreased in time during the first 48h after 
addition of this blocker to the medium. Extended (>48h) incubation with BDM, as performed 
in the SERCA2a mRNA expression study (described in Chapter 2) resulted in a complete 
inhibition of contractile activity and a concomitant disorganization of the actin sarcomere 
structure and a decreased expression of F-actin (described in Chapter 4).  
 
6.2.3. Physiological relevance of the model 
The use of the cross-bridge uncoupler BDM to abolish mechanical load while 
maintaining calcium transients allows the dissection of calcium-dependent and load-
dependent effects of contractile activity, which is not possible in in vivo models of cardiac 
hypertrophy. A major limitation of this experimental set-up is however that a condition with in 
vitro contractile activity is compared with a condition of complete absence of in vitro 
contractile activity, whereas in vivo cardiac hypertrophy develops in response to mechanical 
overload. To impose in vitro contractile activity, cardiomyocytes may be stretched, either 
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continuously or cyclically, to increasing extents 1. Despite this limitation of the model of 
contractile arrest induced by BDM-treatment, the model may be used to elucidate basic 
mechanical load-dependent regulatory mechanisms.   
At the BDM concentration used in this study (7.5 mM), contractile activity is inhibited 
but calcium transients are maintained 2. This allows the dissection of calcium-dependent and 
load-dependent effects of contractile activity, a characteristic that cannot be mimicked in in 
vivo models of cardiac hypertrophy. 
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6.3. A balance between calcium and contractile activity 
6.3.1. Opposing effects of calcium- and contraction-dependent signaling  
In the preceding chapters we have shown that in the in vitro model of isolated 
spontaneously contracting NVCM, a balance between intracellular calcium- and contractile 
activity dependent signaling determines SERCA2a mRNA expression. Impairment of cross-
bridge cycling following a three day experimental protocol of BDM-treatment, while 
maintaining normal calcium transients, stimulated SERCA2a mRNA expression (Figure 2 
panel A), which was accompanied by a fall in ANF mRNA expression. Other studies using  in 
vitro models of enhanced cellular stretch 3-5 or in vivo models of enhanced mechanical load 
6,7 demonstrate a similar regulatory mechanism, i.e., repression of SERCA2a expression by 
enhanced load. Since calcium-dependent signaling is also activated in these in vivo models 
of pressure overload induced hypertrophy 8-12, this indicates that the negative effect of 
contractile load most likely overrides the stimulatory effects of calcium-dependent signaling 
under this condition (Figure 2; panel B).  
 
6.3.2. The positive side of the balance: calcium and SERCA2a transcription regulation 
In Figure 2, a hypothetical representation is given of SERCA2a mRNA expression 
regulation by contractile activity- and calcium-dependent signaling during the time course of 
the in vitro experiments described in Chapter 2. Three days of BDM-treatment results in a 
complete loss of contractile activity (panel A, green), while calcium transients are maintained 
(Muller et al. unpublished results) 2. Although CN and CAMK-II activities were not directly 
determined in this experimental protocol, unaltered nuclear accumulation of NFATc-GFP in 
BDM-treated NVCM as compared to spontaneously contracting NVCM suggests that CN 
activity is preserved in non-contracting NVCM (panel A, blue). Experiments determining 
endogenous NFAT levels suggest that CN-signaling may even be increased in contraction-
arrested NVCM. The absence of the inhibitory effects of contractile activity and the 
concomitant preservation of the stimulatory effects of calcium-dependent signaling result in 
enhanced SERCA2a mRNA expression (panel A, red) as observed in this study 13. Panel B 
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of Figure 2 gives a hypothetical representation of the relationship between SERCA2a 
expression during the process of hypertrophy and heart failure and load- and calcium-
dependent signaling, based on the results obtained in the in vitro studies described in this 
thesis. After the onset of a hypertrophic stimulus, e.g., hypertension, mechanical load of the 
heart will rapidly increase (Figure 2 Panel B, green). Parallel to this increase in load, calcium-
dependent CN and CAMK-II cascades will be activated 9,10. Due to the simultaneous increase 
in load- and calcium-dependent signaling, SERCA2a transcription will not decrease in the 
phase of compensatory hypertrophy, or may even increase when the effect of the calcium-
dependent signaling exceeds that of the load-dependent signaling (Figure 2 panel B, blue). 
Enhanced SERCA2a expression is sometimes observed during physiological cardiac 
hypertrophy 14. Load-dependent signaling will be maintained when the load stimulus is 
maintained chronically. However, the stimulatory calcium-dependent CN and CAMK-II 
signaling cascades may be countered by stress-induced cascades (discussed in more detail 
in the sections 6.3.3.) 15,16 (Figure 2, panel B, blue), resulting in repressed SERCA2a 
expression, which is a common feature of the end-stage of pathological cardiac hypertrophy 
(Figure 2, panel B, red) 6,17-21  
The calcium-dependent stimulation of SERCA2a appeared to be largely CN and 
CAMK-II dependent, which is in agreement with previous studies describing a stimulatory 
role of CN signaling in SERCA2a protein regulation in skeletal muscle 22 and the heart 23. On 
the other hand, calcium-dependent signaling is considered to be essential for the 
development of pressure-overload induced pathological hypertrophy and many of the 
concomitant changes in gene expression, including downregulation of SERCA2a expression 
24. Shimoyama et al. showed that inhibition of CN signaling in an in vivo model of pressure-
overload induced hypertrophy resulted in an increased SERCA2a mRNA expression 8 . In 
addition, cardiac overexpression of a constitutively active form of CN or CAMK in transgenic 
mice resulted in decreased SERCA2 mRNA expression 25, whereas in transgenic mice with 
cardiac overexpression of a dominant negative form of CN, SERCA2a mRNA levels were 
maintained at control levels when these mice were subjected to hypertrophy induced by 
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pressure overload 26. However, these in vivo models suffer from the shortcoming that indirect 
effects of calcium-dependent signaling cannot be distinguished from direct effects on 
SERCA2a expression. Furthermore, the obligatory interaction of calcium and mechanical 
load in vivo renders it almost impossible to distinguish the individual effects of calcium- and 
mechanical load-dependent signaling in the repression of SERCA2a expression. Given these 
considerations, we suggest that the stimulatory effects of calcium-dependent signaling in the 
regulation of SERCA2a expression are overruled by the more prominent negative effects of 
sustained activation of load-dependent cascades (Figure 2; panel B).  
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Figure 2 
Hypothetical representation of changes in mechanical load-dependent factors  (green) and calcium-
dependent signaling (blue) and SERCA2a expression (red) during A. In vitro BDM-induced contractile 
arrest B. pressure-overload induced pathological cardiac hypertrophy and C. pressure-overload 
induced pathological cardiac hypertrophy with LVAD support. Numbers in the panels represent: 1. 
Complete in vitro contractile arrest at day three of the experimental protocol following BDM-treatment; 
2. Onset of pathological hypertrophic stimulus; 3. Increase in load and calcium-dependent signaling, 
which may result in enhanced SERCA2a expression when the calcium-dependent signaling prevails; 
4. Attenuation of the stimulatory effects of calcium-dependent signaling under conditions of  
chronically increased load  will result in a repression of SERCA2a expression; 5. LVAD support of the 
failing  heart attenuates the negative effects of load-dependent signaling, resulting  in renormalization 
of  SERCA2a expression (panel C is discussed in section 6.4.). See text for details. 
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6.3.3. Negative side of the balance: contractile activity and SERCA2a transcription  
6.3.3.1. Direct effects of contractile activity    
The observed negative effect of mechanical load in the regulation of SERCA2a 
mRNA expression is also described by several other groups 27-30. Two mechanisms may be 
proposed to explain reduced SERCA2a transcription due to contractile activity.  
The first possibility is that contractile activity activates one or multiple signaling 
cascades that directly repress SERCA2a promoter activity. In Chapter 3 the role of such a 
cascade, the RhoA-ROCK-SRF signaling pathway, was investigated. Previously, increased 
RhoA activity has been observed during pathological cardiac hypertrophy 31,32. As RhoA 
signaling is closely linked to actin dynamics and as contractile arrest results in a 
desintegration of the actin sarcomere structure 33-36, it is likely that load-dependent RhoA-
mediated signaling is impaired following contractile arrest. Impaired RhoA signaling will result 
in limited effects of its downstream factors in on transcriptional regulation. In this study 
(Chapter 3) it was shown that SRF, one of the downstream transcription factors in RhoA-
ROCK mediated signaling, is involved in upregulation of ANF transcription via the interaction 
with myocardin and that SRF is involved in the downregulation of SERCA2a transcription 
regulation via the interaction with an as yet undetermined factor. Since these promoter 
studies were performed in COS7 cells, it remains to be established that SRF together with 
myocardin indeed plays a role in transcriptional regulation of ANF transcription in NVCM, and 
this also applies to the role of SRF in the regulation of SERCA2a transcription. In contrast to 
the in vivo model of pathological cardiac hypertrophy as described by Davis et al. 37, SRF 
splice variants were not observed in spontaneously contracting NVCM. This may indicate 
that the load induced by in vitro contractile activity is not severe enough to generate these 
splice variants 38. In addition to RhoA signaling, other contractile-activity dependent cascades 
such as reactive oxygen species (ROS)-dependent activation of MAPK pathways 39,40,41 and 
their respective transcription  factors such as NF-κB 42,43, may contribute to repression of 
SERCA2a transcription and expression. Effects of MAPK pathways, in particular p38 MAPK 
will be discussed in the next section. Direct effects of NF-κB on SERCA2a transcription 
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regulation is conceivable, as sequence analyzes of the rat SERCA2a promoter have 
identified NF-κB responsive elements located in the proximal region of the SERCA2a 
promoter that is conserved among species. 
 
6.3.3.2. Indirect effects of contractile activity 
As a second possibility, reduced SERCA2a transcription due to mechanical load may 
result from indirect effects. Several different mechanisms may be proposed by which 
contractile activity counters the stimulatory effects of CN activity. These mechanisms are 
depicted in Figure 3. Firstly, contractile activity activates several cytosolic stress-induced 
kinases such as JNK 39,44, p38 MAPK 39, MCIP 45 and GSK3β 46 that have been shown to be 
able to directly modulate CN activity (Figure 3 [1], reviewed by Fiedler and Wollert 47), or 
prevent CN-dependent dephosphorylation of NFAT (Figure 3 [2]), as already described in 
Chapter 3. In addition, it is also possible that JNK, p38 MAPK, MCIP, GSK3β or casein 
kinase 48 are more active in the nucleus under conditions of contractile activity, thereby re-
phosphorylating NFAT, resulting in enhanced nuclear export of NFAT via Crm-1-
(in)dependent mechanisms 49 (Figure 3 [3]). Once the balance between nuclear export and 
nuclear import of NFATc4 is shifted towards nuclear export, the synergistic interaction 
between NFATc4 and MEF2c that results in increased SERCA2a transcription will also 
diminish (Figure 3 [4]).  
A shift towards increased nuclear export of NFAT as an underlying mechanism of 
impaired SERCA2a transcription in contracting NVCM was assessed in Chapter 2 and in 
Chapter 3. Life cell imaging of GFP-coupled NFATc revealed that nuclear localization of 
transfected NFATc-GFP was independent of the contractile activity of NVCM (Chapter 2). 
However, in Chapter 3 immunohistochemical analyzes of endogenous NFATc4 showed an 
increased nuclear accumulation of this transcription factor following contractile arrest. This 
indicates that contractile activity has either different effects on various NFAT isoforms, or that 
levels of transfected NFATc-GFP may have exceeded the capacity of endogenous regulatory 
systems. Increased nuclear accumulation of NFATc4 in contraction-arrested NVCM suggests 
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that next to direct inhibitory cascades, such as the RhoA-ROCK-SRF pathway (Chapter 4), 
also control of nuclear export and import of stimulatory transcription factors such as NFATc4 
determine the level of SERCA2a transcription. Whereas CN activity increases nuclear import 
of NFAT, GSK3β is one of the factors that controls nuclear export of NFATc4. When active, 
GSK3β stimulates nuclear export of NFATc4, but also of other transcription factors such as 
GATA4 50-52. Western blot analyzes revealed that contractile arrest reduces the activity of 
GSK3β, which may explain the concomitant nuclear accumulation of the transcription factors 
NFATc4 and GATA4 during contractile arrest. Recently, Michael et al. 53 also described an 
inhibitory role of GSK3β in the control of SERCA2a transcription, mRNA and protein 
expression in GSK3β-overexpressing mice. Due to the effects of GSK3β on nuclear export of 
both NFATc4 and GATA4, this kinase may play a central role in the regulation of SERCA2a 
transcription.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 
Overview of the mechanisms by which mechanical load may counter the stimulatory effects of CN 
activity on SERCA2a transcription (see text for details).  
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6.4. In vivo unloading of failing hearts using left ventricular assist devices (LVAD) 
An in vivo condition that may resemble to some extent in vitro contractile arrest is the 
use of human left ventricular assist devices (LVAD). To bridge the period preceding cardiac 
transplantation, patients may receive LVAD to support the failing heart and reduce 
hemodynamic overload. Long-term treatment of patients with LVAD has shown to be 
beneficial with respect to cardiac function by inducing a process called reverse remodelling 
of the failing heart. This process includes: 1) improvement of cardiac relaxation due to 
increased expression of calcium handling proteins, such as SERCA2a 54, or NCX 55, and 2) 
reduction of the contribution of stress-induced signaling cascades including ERK1-2, Akt and 
SRF 56-58. These results suggest that mechanical unloading using LVAD attenuates the 
negative effect of stress- and load-dependent signaling pathways (Figure 2 panel C, green), 
resulting in a dominant role of stimulating mediators in the expression of calcium regulating 
proteins such as SERCA2a, similar to the effects observed during in vitro contractile arrest 
(compare Figure 2 panel A and C). 
 
6.5. Relevance of GATA4 dependent stimulation of SERCA2a transcription 
As discussed earlier, GSK3β not only affects nuclear levels of NFAT, but is also 
involved in the regulation of nuclear levels of GATA4. As described in Chapter 3, the nuclear 
level of GATA4 is increased following contractile arrest, which correlated with a decreased 
GSK3β activity, mediated by signaling distinct from Akt. Possibly, Wnt signaling 51, or 14-3-3 
59 are involved in GSK3β inactivation in contraction-arrested NVCM. Since GATA4 is known 
to play an inhibitory role in the process of apoptosis 60, the reduced GSK3β activity and 
subsequent increase of nuclear GATA4 in contraction-arrested NVCM may represent a 
mechanism to prevent apoptosis of the cardiomyocytes.  
In Chapter 3, it was shown that GATA4, in addition to NFATc4 and MEF2, may also 
contribute to increased SERCA2a promoter activity induced by contractile arrest of NVCM. 
The newly identified GATA4 consensus site that is likely to be involved in the stimulatory 
effect of GATA4 on SERCA2a promoter activity is located upstream of the 4.1 kb promoter 
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sequence which is highly homologous to the mouse sequence (discussed in more detail in 
the next section). Its contribution to the stimulatory effect of GATA4 awaits further 
examination.  
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6.6. Physiologically relevant length of the SERCA2a promoter sequence 
Transient transfection experiments using plasmid DNA constructs of promoter 
sequences and reporter genes are generally used to investigate the possible contribution of 
(transcription) factors in the regulation of promoter activity 13,28,29,61-63, although this approach 
does not allow analysis of in vivo transcription regulatory processes, such as histon 
modification. In vitro dissection of the individual effects of different “pro-hypertrophic” 
signaling cascades in SERCA2a transcription regulation revealed a stimulatory effect of the 
transcription factors NFAT, MEF, and GATA4 that were formerly considered to repress 
SERCA2a promoter activity or expression 25,62,64. Using different 5’-ends of the rat SERCA2a 
promoter sequence, differences in SERCA2a promoter responses following overexpression 
of the various transcription factors were observed, indicating that the same transcription 
factor can act as a repressor or as an activator on the same promoter depending on the 
promoter length. This is of importance in interpreting our results. As described in Chapter 2, 
SERCA2a mRNA expression was stimulated by CN and CaMK-II-dependent signaling 
following contractile arrest of NVCM. In contrast, analyzes of the rat SERCA2a promoter 
activity of deletion variants up to -3200 bp revealed an NFATc4 and MEF2c-dependent 
repression. However, transfection of the 6.6 kb promoter sequence together with the 
calcium-dependent transcription factors revealed an increase in SERCA2a promoter activity, 
in line with increased SERCA2a mRNA expression. The physiological relevance of the 
results obtained with this extended promoter fragment is further supported by the finding that 
in vivo gene transfer of the 6.6 kb promoter sequence in control rats resulted in a level of 
promoter activity that was similar to the activity of the shorter SERCA2a promoter fragments. 
Furthermore, the physiological relevance of the longest SERCA2a promoter fragment is 
supported by the high degree of homology between the rat and mouse SERCA2a promoter 
sequence 13 up to 4.1 kb. Comparison of the murine SERCA2a promoter sequence with the 
human SERCA2a promoter sequence revealed only limited sequence homology 62. However, 
GATA4, NFAT, MEF and SRF responsive transcription boxes are also identified in the 
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human promoter sequence, indicating that the mechanisms elucidated in the current rat 
study may also apply to regulation of the human SERCA2a promoter.    
 
6.7. Future experiments  
 
6.7.1. Proposed future in vitro experiments 
In section 6.2.3 the issue was raised that contractile arrest is an unphysiological 
condition for cardiomyocytes. The use of an experimental setup of enhanced mechanical 
load would increase the insight into in vitro load-dependent control of SERCA2a 
transcription. Mechanical load of spontaneously contracting NVCM may be enhanced by 
electrical stimulation of contraction at various frequencies or by stretching NVCM that are 
adhered to a flexible membrane to increasing extents, either continuously or cyclically 3-5,65. 
The contribution of various transcription factors or components of signal transduction routes 
in SERCA2a transcription regulation may be investigated using for example the technique of 
RNA-interference to specifically degrade transcription factors or components of signaling 
routes of interest. Candidates for this approach are the load-dependent kinase RhoA and its 
downstream transcription factor SRF 66 and the calcium-dependent kinase CAMK or 
phosphatase CN and their respective transcription factors NFAT and MEF2 67.  
Based on the results described in this thesis the physiologically relevant length of the 
rat SERCA2a promoter extends to at least 4.1 kb. The involvement of specific binding 
domains for inhibitory or stimulatory transcription factors involved in SERCA2a transcription 
regulation that are located in the upstream region of the SERCA2a promoter may be 
investiged by direct mutagenesis of these sites. Moreover, it is essential to translate the in 
vitro obtained results with respect to SERCA2a regulation, to an in vivo context.  
 
6.7.2. Proposed future in vivo experiments 
Because plasmid DNA used in in vivo transient transfection analysis of promoters is 
not subjected to regulation involving histone proteins, the response of such promoters to 
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transcription factors may differ from that of endogenous promoter DNA. Upstream promoter 
sequences that are accessible to transcription factors in the context of plasmid DNA 
constructs, may not be accessible in the genomic context, resulting in a different response to 
signaling cascades and their corresponding transcription factors. To circumvent this problem, 
endogenous SERCA2a promoter activity can in principle be monitored in in vivo models of 
pathological hypertrophy using nuclear run-on assays 30. However, the nuclear run-on assay 
is an elaborative technique requiring a large amount of cardiac tissue, and for that reason not 
feasible for this purpose. Moreover, specific load- or calcium-dependent regulatory elements 
that are involved in regulation of SERCA2a transcription can not be characterized by this 
technique. The technique of in vivo gene transfer does allow the assessment of the 
contribution of individual regulatory sites in the regulation of SERCA2a transcription. In 
Chapter 5 it was shown that direct gene transfer following in vivo injections is a promising 
technique to investigate in vivo (load-dependent) SERCA2a transcription regulation. A 
limitation of the technique is the relatively low transfection efficiency. This may be improved 
by alternative techniques such as adenoviral infection with SERCA2a promoter-Luciferase 
constructs. Disadvantages of this technique are, however, that other cardiac cell types in 
addition to cardiomyocytes will be infected, that other tissues may be infected and that 
immune responses may be elicited. The use of magnetofection 68 of reporter plasmids in the 
heart may reduce the immune responses and will restrict the transmission to the heart.  
Due to the transient nature of the expression profiles of introduced promoter-
Luciferase constructs, it is important to determine the ideal time point to transfer the DNA into 
the myocardium during the development of cardiac hypertrophy. In vivo non-invasive 
techniques such as echocardiography may be helpful to determine this time point in each 
individual animal (Figure 4).    
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Figure 4. Representative M-mode images of one control rat (upper two images) and one rat that is 
subjected to a hypertrophic stimulus (HYP) (lower two images), showing cardiac function and 
dimensions at day –4 and day 21 of the experimental protocol. Note the increased RV wall thickness 
[1] and the increased septal thickness [2] of the HYP rat at day 21 compared to the control RV at day 
21.  
 
6.8. SERCA2a as a therapeutic target in treatment of pathological cardiac hypertrophy  
Downregulation of SERCA2a expression is generally considered to play a critical role 
in the development of heart failure. Impairment of SERCA2a activity is typically seen during 
the later stages of the hypertrophic response and it is often associated with the transition 
from compensated hypertrophy to overt failure 69. Evidence for a critical role of reduced 
SERCA2a activity was obtained by studies using transgenesis or adenoviral gene transfer to 
alter ventricular SERCA2a expression in animal models of heart failure. In gene-targeted 
mice with reduced SERCA2a expression (SERCA2a+/-) 70, the onset of heart failure induced 
by pressure overload was accelerated as compared to wild-type mice. Conversely, in 
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transgenic mice overexpressing SERCA2a, mortality due to pressure overload-induced heart 
failure was effectively reduced 71. In a number of studies, SERCA2a gene transfer by 
adenoviral transfection was employed in the late stages of pressure-overload induced 
hypertrophy, preceding the transition to failure. This resulted in normalized SERCA2a 
activity, restored contraction and relaxation rates and improved survival, emphasizing the 
critical role of reduced SERCA2a activity in this model of heart failure 72,73. In addition, 
positive effects of transfer of SERCA2a on calcium handling were observed in isolated 
human cardiomyocytes from heart failure patients 74. Taken together, this suggests that 
SERCA2a expression is a candidate therapeutic target in the treatment of pathological 
cardiac hypertrophy and heart failure. Adenoviral SERCA2a gene transfer is the most direct 
way of selectively increasing the expression of this enzyme. The development of viral vectors 
with greater cardiac tropism and sustained expression of the transfected gene perhaps 
allows such therapy in the future. Next to adenoviral gene transfer, another way of 
modulating SERCA2a expression levels may be through modulation of the signal 
transduction pathways and transcription factors involved in its regulation. Interestingly, LVAD 
therapy may already target SERCA2a expression in this way. It was recently shown that 
mechanical unloading of the failing heart using LVAD resulted in an improvement of cardiac 
function and an enhanced SERCA2a expression 54. The activity of several stress-induced 
signaling cascades and transcription factors is reduced in LVAD-supported hearts, which 
may, according to the results obtained in this study, underlie the beneficial effects on 
SERCA2a expression. 
The in vitro studies described in Chapter 2, 3 and 4 of this thesis gave rise to a new 
perspective on regulation of SERCA2a expression. Signaling pathways that are generally 
assumed to repress SERCA2a expression, such as the calcium-dependent CN and CAMK-II 
cascades and GATA4 dependent cascades appeared to stimulate SERCA2a transcription. 
This suggests that these routes, that are considered to play a principal role in the process of 
pathological hypertrophy and heart failure, may have positive effects in addition to their 
negative effects. Therefore, caution is warranted when developing therapeutic strategies 
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aimed at eliminating these signal transduction routes, for example the CN-pathway, in the 
hypertrophic heart, since SERCA2a expression may be negatively affected.  
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7.1. Summary 
Decreased SERCA2a mRNA and protein expression is commonly observed in 
pathological cardiac hypertrophy and cardiac failure. There is evidence to suggest that the 
reduced SERCA2a expression results from a repression of SERCA2a promoter activity. 
Effects of pro-hypertrophic signaling pathways on SERCA2a expression or direct effects of 
pro-hypertrophic transcription factors on SERCA2a promoter regulation are, however, largely 
unexplored. This thesis focused on the role of several of these pathways and their 
corresponding transcription factors involved in calcium and contractile activity-mediated 
SERCA2a expression. Furthermore,  the rat SERCA2a promoter (6.6 kb) is characterized.  
In Chapter 1, general information is given about cardiac hypertrophy and signaling 
pathways that are involved in the development of pathological cardiac hypertrophy and heart 
failure. Furthermore, the aim of the study and the in vitro model of spontaneously contracting 
neonatal cardiomyocytes (NVCM) are described.  
In Chapter 2, effects of calcium-dependent signaling through calcineurin (CN) and 
calmodulin-dependent protein kinase-II (CAMK-II) on SERCA2a expression were dissociated 
from effects of contractile activity in spontaneously contracting NVCM, using 2,3-butanedione 
monoxime (BDM) to arrests contractions while maintaining calcium fluxes. Following 
contractile arrest with BDM, upregulation of SERCA2a mRNA expression by CN/CAMK-II 
signaling became evident. This upregulation is likely the result of synergistic stimulation of 
the 6.6 kb SERCA2a promoter activity by NFATc4 and MEF2c. High homology between the 
rat and mouse SERCA2a promoter sequence indicated that the physiologically relevant 
length of this promoter extendeds to at least 4.1 kb. This fragment contains NFAT consensus 
sites and a conserved MEF2c consensus site located at 3713 bp that may contribute to the 
NFATc4 and MEF2c-mediated increase in SERCA2a promoter activity. Contractile activity 
appeared to oppose this calcium-dependent upregulation of SERCA2a mRNA expression 
through distinct and independent pathways.   
Repression of SERCA2a transcription may underlie the load-dependent 
counterbalance of the calcium-dependent stimulation of SERCA2a mRNA expression. A 
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candidate mediator that may be involved in this process is the load-induced transcription 
factor GATA-4. Previously, GATA-4 consensus sites have been identified in the proximal 
regions of the human and rat SERCA2a promoter. However, their role in SERCA2a 
transcription regulation was unknown. In Chapter 3, a novel GATA-4 consensus site was 
identified in the rat SERCA2a promoter located at -5625 bp. Transfection studies revealed a 
muscle-specific stimulatory effect of GATA-4 on SERCA2a promoter activity, which is likely 
to be dependent on this novel GATA-4 consensus site. Furthermore, the role of GATA-4 in 
load-dependent SERCA2a regulation in NVCM was investigated in the model of 
spontaneously contracting and contraction-arrested NVCM.  Contractile arrest resulted in an 
increased nuclear accumulation of GATA-4, which may contribute to the earlier observed rise 
in SERCA2a mRNA expression in contraction-arrested NVCM. The increased nuclear 
accumulation of GATA-4 in contraction-arrested cardiomyocytes appeared to be mediated by 
a decreased activity of GSK3β. These findings were supported by the observation that 
pharmacological repression of GSK3β activity resulted in enhanced SERCA2a transcription. 
Direct load-dependent effects of the RhoA-ROCK-serum response factor (SRF) 
signaling cascade in the regulation of SERCA2a and ANF gene transcription by contractile 
activity were investigated in Chapter 4.  
Contractile arrest of NVCM reduced total RhoA expression, limited its distribution to 
peri-nuclear regions and reduced nuclear SRF, as did treatment of contracting NVCM with 
the ROCK inhibitor Y-27632. Treatment with Y-27632 increased the 6.6 kb SERCA2a  
promoter activity and decreased pANF activity. To exclude cardiac-specific effects, 
transfection experiments were performed in COS7 kidney cells. Only a combination of SRF 
and myocardin stimulated pANF activity, but the same combination failed to alter SERCA2a 
promoter activity. Control by SRF of SERCA2a promoter activity was further assessed in 
COS7 kidney cells cultured in serum-containing medium. Under these conditions, SRF 
lowered SERCA2a promoter activity. This implies  the presence of a serum-dependent co-
factor necessary for SRF to regulate SERCA2a promoter activity. 
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This study demonstrates that contractile activity stimulates ANF and represses 
SERCA2a transcription via the RhoA-ROCK-SRF cascade. SRF stimulates ANF transcription 
in the presence of myocardin and represses SERCA2a transcription through an as yet 
unidentified cofactor.  
Previous in vivo studies using transfection of adult myocardium by direct injection of 
SERCA2a promoter-Luciferase plasmids, have demonstrated in a model of left ventricular 
(LV) pressure overload that the proximal 1.8 kb rabbit SERCA2a promoter fragment contains 
load-responsive elements.  However, the high homology observed between the mouse and 
rat SERCA2a promoters indicates that the physiologically relevant length of the murine 
SERCA2a promoter may extend to at least 4.1 kb. In Chapter 5, we tested whether the 
technique of in vivo DNA transfer can be used to analyze transcriptional activity of SERCA2a 
promoter fragments of up to 6.6 kb in length. In addition, the technique was optimized for  
transfection of the RV in addition to the LV. This allows the use of either RV or LV pressure-
overload models, with the non-hypertrophic ventricle serving as a control for the overloaded 
ventricle. Hearts were exposed via a right-sided thoracotomy and Firefly luciferase (Luc) 
reporter plasmids driven by 0.5, 3.2 or 6.6 kb of the SERCA2a promoter were injected into 
the free wall of both the LV and RV. Five days later, Luc expression was determined in 
ventricular homogenates and normalized using the activity of a co-transfected Renilla 
luciferase reporter plasmid driven by the CMV promoter (CMV-Ren). The success rate of the 
in vivo transfections was 56% for LV and 81% for RV injections. In 45% of the experiments, 
both RV and LV of the same heart were successfuly transfected. Normalized pS2-Luc activity 
increased with increasing length of the S2-promoter. There were no significant differences in 
transcriptional activity of the pS2-Luc constructs between LV and RV. Finally, the method 
was tested for use with the model of monocrotaline (MCT)-induced pulmonary hypertension 
and subsequent RV hypertrophy and failure. Hearts of MCT-treated rats (n=6, 80mg MCT/kg) 
were transfected with pS2-6.6 Luc and CMV-Ren at day 16 following MCT administration and 
analyzed at day 21. The success rates of RV and LV transfections and levels of pS2-6.6 luc 
activity were similar to those found for control rats. In conclusion, the experimental protocol 
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described here allows promoter analysis in both LV and RV in vivo. Furthermore, the 
presented data show for the first time that the SERCA2a promoter of 6.6 kb in length directs 
strong transcriptional activity in vivo, which warrants further analysis of the regulatory 
properties of the far-upstream part of this promoter.   
In Chapter six, the results obtained in this thesis regarding SERCA2a transcription 
regulation are discussed with respect to the in vivo process of pathological cardiac 
hypertrophy and heart failure. Furthermore, suggestions for future research investigating the 
role of in vitro contractile activity, calcium-dependent signaling and in vivo mechanical load in 
SERCA2a regulation are proposed. 
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7.2. Samenvatting 
Pathologische cardiale hypertrofie wordt gekenmerkt door een verlaging van 
expressie van SERCA2a mRNA en eiwit. Er zijn aanwijzigen dat een verminderde 
promotoractiviteit van SERCA2a ten grondslag ligt aan deze verlaagde SERCA2a expressie. 
De effecten van pro-hypertrofe signaaltransductie-routes op de expressie van SERCA2a, en 
de directe effecten van pro-hypertrofe transcriptiefactoren op de regulatie van SERCA2a 
promotoractiviteit, zijn tot nu toe slechts in beperkte mate onderzocht. In dit proefschrift staan 
de effecten centraal van een aantal pro-hypertrofe routes en de bijbehorende 
transcriptiefactoren, die betrokken zijn bij calcium- en contractie-afhankelijke regulatie van 
SERCA2a expressie. Daarnaast is de 6.6 kb sequentie van de SERCA2a promotor van de 
rat gekarakteriseerd.  
In Hoofdstuk één wordt een globaal overzicht gegeven van signaaltransductieroutes 
die betrokken zijn bij de ontwikkeling van pathologische cardiale hypertrofie. Daarnaast wordt 
het doel van dit proefschrift uiteengezet en wordt informatie gegeven over het gebruikte in 
vitro model van spontaan contraherende neonatale ventriculaire cardiomyocyten (NVCM).  
In Hoofdstuk twee wordt het onderscheid gemaakt tussen de effecten van calcium-
afhankelijke calcineurine (CN) en calmoduline-afhankelijke protein kinase II (CAMK-II) 
signaaltransductie enerzijds, en de effecten van contractie-afhankelijke signaaltransductie op 
SERCA2a expressie anderzijds, door gebruik te maken van 2,3-butanedione monoxime 
(BDM), een blokker die contractie remt, maar calciumtransiënten handhaaft. BDM-
behandeling van NVCM resulteerde in een verhoogde expressie van SERCA2a mRNA, 
welke CN- en CAMK-II-afhankelijk bleek te zijn. Deze calcium-afhankelijke stimulatie is 
waarschijnlijk het gevolg van een synergistisch stimulatie van de 6.6 kb SERCA2a 
promotoractiviteit door de calcium-afhankelijke transcriptiefactoren NFATc4 en MEF2c Op 
basis van de hoge mate van homologie tussen de SERCA2a promotor van de rat en de 
muis, lijkt de fysiologisch relevante lengte van de SERCA2a promoter minimaal 4.1 kb te zijn. 
Het SERCA2a promotorfragment tot 4.1 kb bevat een aantal NFAT consensus sites en een 
geconserveerde MEF2c consensus site welke gelocaliseerd is op 3713 bp. Deze MEF2c-box 
  Summary & Samenvatting 
 
 
 
157
zou kunnen bijdragen aan de NFATc4-en MEF2c-gemedieerde stimulatie van de SERCA2a 
promotoractiviteit. Contractie bleek deze calcium-afhankelijke stimulatie van SERCA2a 
mRNA-expressie te remmen via verschillende, onafhankelijke routes. 
Inhibitie van SERCA2a transcriptie zou ten grondslag kunnen liggen aan de 
contractie-afhankelijke remming van de calcium-afhankelijke stimulatie van SERCA2a mRNA 
expressie. Een factor die betrokken zou kunnen zijn bij dit proces is de transcriptiefactor 
GATA4. GATA4 consensus sites zijn al eerder geïdentificeerd in de proximale regio’s van de 
SERCA2a promotorsequentie van de rat en de mens, echter de rol van GATA4 in de 
regulatie van SERCA2a-transcriptie was nog onbekend. In Hoofdstuk drie is een nieuwe 
GATA4 consensus site geïdentificeerd in de sequentie van de rattenpromotor op 5625 bp. 
De bijdrage van deze GATA4 consensus site lijkt van essentieel belang te zijn in de 
spierspecifieke GATA4-afhankelijke stimulatie van SERCA2a promotoractiviteit. Daarnaast is 
de rol van GATA in contractie-afhankelijke regulatie van SERCA2a onderzocht in NVCM. 
Deze studie laat zien dat remming van contracties door BDM een toename van GATA4 in de 
kern veroorzaakt. Een verminderde activiteit van GSK3β lijkt deze toename te veroorzaken. 
Dit wordt ondersteund door de waargenomen stimulatie van SERCA2a promotoractiviteit 
door farmacologische remming van GSK3β. 
Directe contractie-afhankelijke effecten van RhoA-ROCK-Serum Response Factor 
(SRF) signaaltransductie op de regulatie van transcriptie van SERCA2a en ANF zijn 
onderzocht in Hoofdstuk vier. Remming van contractie resulteerde in een verminderde 
RhoA-expressie en beperkte de localisatie van dit eiwit tot meer peri-nucleaire regio’s en 
veroorzaakte een verminderde nucleaire expressie van SRF. Hetzelfde resultaat werd 
gevonden bij behandeling met  de ROCK-remmer Y-27632. Behandeling met deze remmer 
verhoogde de 6.6 kb SERCA2a promotoractiviteit en verminderde de ANF promotoractiviteit. 
Om hartspecifieke effecten te kunnen uitsluiten, werden transfectie-experimenten uitgevoerd 
in COS7 niercellen. Alleen wanneer SRF in combinatie met myocardine werd 
getransfecteerd veroorzaakte dit een stimulatie van ANF promotoractiviteit, maar deze  
combinatie had geen effect op de SERCA2a promotoractiviteit. Het effect van SRF op 
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SERCA2a promotoractiviteit werd eveneens onderzocht in COS7 niercellen die gekweekt 
werden in serum-houdend medium. Onder deze kweekconditie remde SRF de 
promotoractiviteit van SERCA2a. Dit laat zien dat SRF in aanwezigheid van een serum-
afhankelijke co-factor de SERCA2a promotoractiviteit kan remmen. Deze studie toont aan 
dat contractie de transcriptie van ANF stimuleert en de transcriptie van SERCA2a remt via 
de RhoA-ROCK-SRF route. SRF stimuleert ANF transcriptie in de aanwezigheid van 
myocardine en remt SERCA2a transcriptie via de interactie met een tot nu toe niet-
geïdentificeerde co-factor. 
In voorgaande in vivo studies waarbij adulte hartcellen getransfecteerd zijn met 
SERCA2a promotor-Luciferase plasmiden, is in een model van linker ventrikel (LV) 
drukoverbelasting aangetoond dat de proximale 1.8 kb SERCA2a promotor (konijn) 
regulatoire elementen bevat die gevoelig zijn voor mechanische belasting. Echter, de hoge 
mate van homologie tussen de sequentie van de SERCA2a promotor van de muis en de rat 
wijst erop dat de fysiologisch relevante lengte van de promotor mogelijk  4.1 kb bedraagt. In 
Hoofstuk vijf testten we de mogelijkheid om reporter-plasmiden met SERCA2a 
promotorfragmenten tot een lengte van 6.6 kb  rechtstreeks te injecteren  in zowel de LV als 
de rechter ventrikel (RV) van het volwassen rattenhart. Deze techniek stelt ons in staat om in 
zowel RV- als LV-drukoverbelastingsmodellen, de niet-hypertrofe ventrikel als interne 
controle van de hypertrofe ventrikel te gebruiken. Harten werden benaderd via rechtszijdige 
thoracotomie en Luciferase (Luc) reporter-plasmiden, aangedreven door SERCA2a 
promotorfragmenten van 0.5 kb, 3.2 kb of 6.6 kb lengte, werden geïnjecteerd in de vrije wand 
van zowel de LV als de RV. Vijf dagen later werden Luc activiteiten in ventriculaire 
homogenaten geanalyseerd. De Luc-activiteiten werden genormaliseerd op de activiteiten 
van de ge-cotranfecteerde CMV-Renilla (Ren) Luciferase reporter. In zowel de LV (56 %), als 
de RV (81 %) waren Luc-activiteiten waarneembaar. In 45% van de experimenten waren Luc 
activiteiten in de LV en de RV van hetzelfde hart waarneembaar. Genormaliseerde 
SERCA2a-Luc-activiteiten namen toe met de lengte van de SERCA2a promotor. Er was 
geen verschil in activiteit  tussen de LV en de RV. Tenslotte is deze methode ook getest in 
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een model van monocrotaline (MCT)-geïnduceerde pulmonale hypertensie en RV 
hypertrofie. Harten van MCT-behandelde ratten werden getransfecteerd met SERCA2a 6.6 
kb Luc en CMV-Ren constructen op dag 16 na MCT behandeling. Luc activiteiten werden 
geanalyseerd op dag 21. Met betrekking tot transfectie-efficiëntie en SERCA2a 6.6 kb 
promotor-Luc-activiteiten waren de gevonden resultaten voor de MCT-behandelde ratten 
vergelijkbaar met die van controle ratten. Dit experimentele protocol stelt ons in staat om in 
vivo promotoranalyses in zowel de RV als de LV uit te voeren. Daarnaast is voor de eerste 
keer aangetoond dat de 6.6 kb SERCA2a promotor onder in vivo condities in hoge mate 
actief is. Deze bevinding laat zien dat regulatoire sequenties die upstream gelocaliseerd zijn 
in de promotorsequentie van belang kunnen zijn voor de  regulatie van SERCA2a expressie. 
 In Hoofdstuk zes worden de resultaten die beschreven staan in dit proefschrift 
samengevat en bediscussieerd. Afsluitend wordt een aantal aanbevelingen voorgelegd voor 
toekomstig onderzoek met betrekking tot in vitro en in vivo calcium- en contractie-
afhankelijke regulatie van expressie van SERCA2a . 
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Dankwoord 
 
Een terugblik... 
 
….Ik woonde nog bij mijn ouders thuis toen ik net een telefoontje van Dr. Alice Muller had 
gekregen. Dolenthousiast kwam ik naar beneden stormen en vertelde ik mijn ouders dat ik 
op sollicitatiegesprek mocht komen!. Met enigszins zware benen betrad ik de kamer van 
Prof.dr. Tangelder alwaar het eerste gesprek plaatsvond met dr. Muller en Marian Zuidwijk. 
[Eerlijkheid gebied mij te zeggen beste Alice en Marian, ik had mij natuurlijk iets wat 
ingelezen op de “muscle-materie”, maar het sarco-endoplasmatisch reticulum calcium 
ATPase 2a bestuderen in geïsoleerde neonatale rat ventriculaire cardiomyocyten, kwam toch 
wat onbekend voor.].  
Ik dacht dat de sollicitatie er al op zat, maar niets bleek minder waar, ik had er nog twee te 
gaan. Waarbij het eerste gesprek met dr. Warner Simonides en meteen ook het laatste 
gesprek met dr. C. van Hardeveld in een rimboe van planten en lianen het meest is bij 
gebleven. Cor had tijdens dit gesprek steeds over een dop, het duurde even totdat ik door 
had dat Warner de Dop was…, Het echt wetenschappelijk prikkeltje werd wel getrokken door 
onwijs mooie plaatjes van PKC in een hartspiercel van en een meeslepend enthousiast 
verhaal over translocaties van dr. René Musters, het startsein had geklonken voor een mooie 
vier jaar!..... 
 
Het was in het begin zeker niet gemakkelijk. Het kweken van NVCM bleek allerminst 
gemakkelijk. Cellen die niet hechten en dood gingen, cellen die wel hechten en doodgingen, 
cellen die niet doodgingen maar niet samentrekken, cellen in aanwezigheid van circulair 
genomisch materiaal.. etc. etc. Daarom wil ik graag ook met jou, René, beginnen, met de 
mensen van het lab die ontzettend belangrijk zijn geweest in de verschillende fases van het 
promotie traject. René jouw motiverende pep-talk ben ik nog steeds ontzettend dankbaar en 
je fantastisch enthousiaste manier van werken in het donkere imagelab is van groot belang 
geweest om het dieseltje opgang te brengen. Mede dankzij jouw inzet zijn belangrijke 
ondersteunende data voor het eerste gepubliceerde hoofstuk tot stand gekomen.  
Beste professor Paulus, beste Walter, in het tweede jaar raakte u betrokken bij het project 
als vervanger van de met pensioengaande professor Westerhof. Ik heb genoten van de vele 
discussies om de erg basale resultaten in een meer klinisch daglicht te plaatsen en vaak 
lukte dit ook!. Daarnaast is het “helder-beschrijven van de data” een begrip aan het worden. 
Ook in het huidige project hoop ik dat we nog veel kunnen brainstormen en data mogen 
interpreteren.  
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Beste Alice en Dop, jullie hulp bij het oplossen van de zeer moeilijke “vijf-sterren” 
cryptogrammen is van grote waarde. Inzicht krijgen in transcriptie-regulatie van de SERCA2a 
promoter is meer dan de interactie tussen NFAT, MEF, GATA. Het voordeel in deze studie is 
zeker de lengte van de promoter geweest, maar tegelijk ook het nadeel: “Waar moet je nu 
beginnen”; “Welke site moet eruit geknipt worden”; “Wat is fysiologisch van belang”, vragen 
die steeds terugkomen. Maar toch hebben we een klein beginnetje met het oplossen van het 
cryptogram kunnen maken, wellicht kunnen we in de nabije toekomst nog een aantal 
cryptogrammen oplossen. 
En dan natuurlijk mijn roomi, ouwe dibbus en nu ook paranimf, Arthur. Heel blij ben ik dat je 
mijn paranimf wil zijn tijdens de officiële ceremonie. Dit betekent veel voor mij. De ontelbare 
Doppio’s, Cappuccino’s en klonterkoeken waren iets waar ik met zeer warme gevoelens aan 
terugdenk. Vele items zijn de revue gepasseerd, wetenschappelijk, maar ook privé. Met jouw 
komst op de ongetwijfeld meest koffie-drinkende-kamer (Al moet ik zeggen dat de “Arthur-
bak” toch iets te sterk is voor mijn maag) van de VU ging letterlijk een wind door de kamer. 
Het avontuur met de Sita was hierbij wel een van de meest (stoffige) hoogtepunten. 
Ontzettend gezellig zijn daarnaast ook de etentjes, waardoor ook een leuke band met Silvia 
is ontstaan. Veel succes met jouw laatste lootjes van het proefschrift en je opleiding tot 
ongetwijfeld een fantastisch anesthesioloog!.  
Naast Arthur, draag ik Christa in het bijzonder ook een zeer warm hart toe. Het DE-cafe was 
vaak de rustplaats voor ons drieën om allerdaagse dingen te bespreken. Ook jij bent zeer 
belangrijk geweest in beslissende momenten van het AIO-project. Jouw doortastende, 
efficiënte en vooral motiverende manier van werken heeft tot vele successen geleid en dient 
als een groot voorbeeld voor mij. Daarnaast heb je vaak net dat goede voorzetje gegeven 
waardoor ik de bal in kon koppen, de waardering hiervoor is enorm. De echte intensieve 
samenwerking is tot stand gekomen door de dieet-GSK poster, wat uiteindelijk geleid heeft, 
in nauwe samenwerking met Michaela en Margriet, tot het postdoc-project. Christa bedankt 
voor je vertrouwen in mij om door te gaan in deze nieuwe uitdaging!. 
Henk en Everaldo, eveneens mijn roomies en mede-mega-koffie-drinkers, (al blijft Everaldo 
toch de t-leut). Ook jullie hebben B138 tot een, ik zou zeggen, tweede huiskamer gemaakt. 
Henk ik ben blij dat je mij af en toe steunde met het “raam open of dicht issue”. Everaldo 
moet maar wanten aantrekken.. ;). Daarnaast heb je zeker samen met Arthur, Christa, Jan-
Paul en mijn vader een soort van computer-crisisteam gevormd. Een aantal keer hebben 
jullie het onmogelijke toch voor elkaar gekregen en mijn computertjes weer nieuw leven 
ingeblazen!  
Ed en Marten, mijn toekomstige roomies. Waarschijnlijk zit ik bij het verschijnen van dit 
boekje wel net bij jullie op de kamer.. Ed, wanneer gaan we weer varen of wat-lopen ;). We 
zullen ongetwijfeld veel boompjes opzetten over onze DFN-projecten samen met Wieneke. 
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Beeeehhuuhhh Marten, ouwe rheusz, [altijd links], en zeker de photoshop-koning van de 
afdeling. Je duik- en vakantie verhalen deden ons ook nog meer prikkelen om veel van de 
wereld te zien. Het sqwosjuhn was een minder succes, maar eens moet er maar een 
revanche komen. 
De ladiesroom van Marjon, Linda, Amanda en William (mooie stad hé Almere), maar ook 
Nadiya, Loek, Nazha en Mariska en Regis, Marco en Anja bedankt voor alle leuke luchtige 
talks en gezelligheid. Amanda en Marjon, San Diego was zeer geslaagd, wanneer gaan we 
weer? Marjon waardering alom voor je doorzettingsvermogen en veel succes met de 
afronding van jouw proefschrift! En Roelof we spreken nog een keertje af om te vliegen! 
Buurman Richard, het was leuk samen te werken op de celkweeklabjes, ik heb veel genoten 
van de discussies over jouw stretch, mechanische belasting en contractiele activiteit en mijn 
stretch, mechanische belasting en contractiele activiteit, maar we hebben geen golden 
retriever wel een Toyota.  
Marian, ontzettend bedankt voor de technische ondersteuning bij vooral de injectie 
experimenten, jouw nauwkeurigheid zorgvuldigheid heeft menig in vivo experiment tot een 
goed einde weten te brengen. 
Geerten en Cora door jullie RhoA expertise heeft hoofdstuk vier net dat stukje extra 
gekregen. Voor de nabije toekomst hoop ik dat we nog leuke dingen op het β-cat-pad 
tegenkomen!. 
Daarnaast wil ik hier zeker ook Oliver, Laura, Julio, Marein, Joris, Niels, Gieneke en Kanita 
enorm bedanken voor een hele boeiende, gezellige, maar ook voor mij een leerzame 
periode!. 
Hans (ook jouw boekje is afgekomen!), Connie en Aimee volop geniet ik van de “gang-
babbeltjes over ditjes-en-datjes”. Enorm bedankt voor de administratieve ondersteuning. 
Brechje, Ria, Nicky, Iolente, Ingrid, Ruud en Michiel, bedankt voor jullie steun en vooral 
gezelligheid. En zeker wil ik Wim niet vergeten voor de gezellige vrijdagmorgenbabbeltjes 
wanneer ik neo’s kwam halen in de stallen waardoor ik al achter op schema liep voordat ik 
begon aan het experiment. Chris Zwart, de Dam tot Dam 2006 staan we er gewoon weer 
hoor. 
Naamgenoot Ronald en Henk bedankt voor alle goede zorgen en het wederom kalibreren 
van de pipetten. Sjoerd, Micha en Huib eens wint “boven” met karten hoor…, wij hebben nu 
Ingrid!.  Willem,….. tja ook dit jaar wordt Feijenoord niet kampioen ;) 
Koen, Jolanda en professor Tangelder, kortom de feestcommissie, vaak was het net 
allemaal op tijd af maar de voorpret en de labuitjes zelf waren altijd zeer de moeite waard!  
Chris, Janke, Jolanda, Sytse en Karin gouden vrienden, door al de drukte liet ik het wel eens 
afweten, maar jullie zijn het die altijd weer contact opnemen, vanaf nu is het mijn beurt weer!   
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Een blik in de toekomst.. 
 
Inmiddels ligt de AIO periode alweer een tijdje achter mij en zijn we alweer volop bezig met 
nieuwe mooie dingen. Beste Margriet, Michaela en Christa, elke morgen is het weer een 
feest als de mailbox weer over its maximal size is… We hebben al menig -80C vriezerdoosje 
gevuld met materiaal, ongetwijfeld gaat dit een mooie tijd worden.  
 
Thuis… 
 
Door de jaren heen heeft een warm thuis mij geholpen in vele dingen en een basis gevormd 
voor hetgeen wat ik nu kan doen. Tijdens mijn jeugd in Emmeloord bij mijn ouders en later 
ook schoonouders en tevens tijdens mijn studie in Amsterdam bij tante Wil, ome Piet en ome 
Jan en nu in Almere bij jou, Anita. 
Gedurende de afgelopen vier jaar is veel geleerd op wetenschappelijk gebied, maar ook op 
persoonlijk gebied. Lieve Pa en Ma, bijzonder is jullie veerkracht. Vier jaar is te kort om alle 
data te vergaren om alle artikelen te publiceren. Vier jaar is lang wanneer je van het één in 
het ander valt. Jullie interesse voor het onderzoek onder alle omstandigheden maakt juist dat 
de alledaagse problematiek in een heel ander perspectief komt te staan.    
Aan alle leuke dingen komt een eind, hoewel ik de laatste zinnen met gemengde gevoelens 
aan het tikken ben, overheerst toch naast een tevreden gevoel, een gevoel van opluchting. 
Het proefschrift is klaar!. Ik zal zeker niet de enige zijn die dit gevoel kent. Ik spreek zeker 
ook uit naam van Anita. Lieve Anita, mijn steunpilaar, jij verdient de grootste waardering. 
Naast een leuke baan, die van een hobby in een tot een uit de hand gelopen hobby dreigde 
te worden, ben jij het die af en toe aan de rem moest trekken. De laatste tijd heb je veel 
dingen uit mijn handen genomen en veel begrip getoond wanneer ik weer eens ‘s avonds 
moest doorwerken (die koopavonden ook toch..), of een avondje boven achter de computer 
moest doorbrengen, maar het proefschrift was bijna klaar…. Dit boekje is ook tot stand 
gekomen door jouw verdiensten! Zonder een goed thuis was dit niet mogelijk. 
  
 
 
 
 
Wheresoever you go, go with all your heart. 
 
Confucius 
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